

# **Regulation of the pancreatic K<sub>ATP</sub> channel**

Samuel Usher

Green Templeton College  
University of Oxford

*A thesis submitted for the degree of  
Doctor of Philosophy*

Trinity 2021

## **Abstract**



# Regulation of the pancreatic K<sub>ATP</sub> channel



Samuel Usher  
Green Templeton College  
University of Oxford

A thesis submitted for the degree of

*Doctor of Philosophy*

Trinity 2021



# Acknowledgements



# Abstract



# Contents

<b>List of Figures</b>	<b>xi</b>
<b>1 Introduction</b>	<b>1</b>
1.1 General introduction . . . . .	2
1.2 Pancreatic islets and the $\beta$ -cell . . . . .	2
1.3 Architecture of the pancreatic $K_{ATP}$ channel . . . . .	2
1.4 Ligand-independent regulation of the pancreatic $K_{ATP}$ channel . . . . .	5
1.4.1 Assembly and trafficking . . . . .	5
1.4.2 Regulation of intrinsic gating . . . . .	7
1.5 Ligand dependent regulation of the pancreatic $K_{ATP}$ channel . . . . .	7
1.5.1 Nucleotide regulation of the pancreatic $K_{ATP}$ channel . . . . .	7
1.5.2 $PIP_2$ regulation of the pancreatic $K_{ATP}$ channel . . . . .	10
1.5.3 Sulphonylurea regulation of the pancreatic $K_{ATP}$ channel . . . . .	10
1.6 Fluorescence methods in ion channel research . . . . .	10
1.6.1 Fluorescence as a tool . . . . .	10
1.6.2 Forster resonance energy transfer . . . . .	10
1.6.3 Unnatural amino acid incorporation . . . . .	10
1.7 Functional modelling of ion channels . . . . .	10
1.7.1 Why? . . . . .	10
1.7.2 A model that fits . . . . .	10
<b>2 Methods</b>	<b>11</b>
2.1 Molecular biology. . . . .	11
2.2 Cell culture and channel expression . . . . .	12
2.3 Western blots . . . . .	13
2.4 Confocal microscopy . . . . .	14
2.5 Surface expression assays . . . . .	15
2.6 Epifluorescence imaging and spectroscopy . . . . .	16
2.7 Electrophysiology. . . . .	16
2.8 FRET calculations . . . . .	17
2.9 Unroofed binding measurements. . . . .	18
2.10 Patch-clamp fluorometry. . . . .	19

2.11	Data processing and presentation. . . . .	19
2.12	Computational docking. . . . .	20
2.13	Chemicals and stock solutions. . . . .	20
<b>3</b>	<b>Measuring nucleotide binding to K<sub>ATP</sub></b>	<b>21</b>
3.1	Designing a nucleotide binding assay . . . . .	21
3.1.1	Criteria for a useful assay for nucleotide binding to Kir6.2 . . .	21
3.1.2	Choosing a site to incorporate ANAP . . . . .	24
3.2	Incorporating ANAP into the Kir6.2 binding site . . . . .	27
3.2.1	Amber stop codon expression system . . . . .	27
3.2.2	ANAP incorporation into amber stop codon containing constructs	27
3.3	Testing for functional membrane expression . . . . .	29
3.3.1	Surface expression of HA-epitope labelled Kir6.2 constructs . .	29
3.3.2	Electrophysiology of Kir6.2 constructs . . . . .	30
3.3.3	Unroofed membrane binding assay of Kir6.2 constructs . . . .	31
3.3.4	Patch-clamp fluorometry of Kir6.2 constructs . . . . .	33
3.4	Discussion . . . . .	34
<b>4</b>	<b>MWC modelling</b>	<b>45</b>
4.1	Modelling of ion channel function . . . . .	45
4.1.1	Restricting the subset of possible models . . . . .	45
4.1.2	Considerations for fitting a model . . . . .	45
4.1.3	Determining open probability . . . . .	45
4.2	Implementing an MWC model . . . . .	50
4.2.1	A simple case . . . . .	50
4.2.2	The role of PIP <sub>2</sub> . . . . .	50
<b>5</b>	<b>Nucleotide regulation of Kir6.2</b>	<b>57</b>
5.1	Introduction . . . . .	57
5.2	Nucleotide binding . . . . .	59
5.2.1	G334D abolishes nucleotide binding . . . . .	59
5.3	Channel gating . . . . .	61
5.3.1	C166S alters inhibition without affecting binding . . . . .	61
5.3.2	Mutations at E179 alter both inhibition and binding . . . . .	63
5.3.3	Mutations at K39 alter both inhibition and binding . . . . .	66
5.4	Discussion . . . . .	67

<b>6 Regulation of Kir6.2 by SUR1</b>	<b>71</b>
6.1 Introduction . . . . .	71
6.2 Intrinsic effects of SUR1 . . . . .	72
6.2.1 SUR1 alters nucleotide inhibition, but not binding . . . . .	72
6.2.2 Presence of SUR1-TMD0 alone does not alter apparent nucleotide binding . . . . .	74
6.3 SUR1 and nucleotide regulation . . . . .	74
6.3.1 Mutations at SUR-K205 alter nucleotide binding and inhibition	74
6.4 Discussion . . . . .	76
<b>7 Discussion</b>	<b>79</b>
<b>Appendices</b>	
<b>References</b>	<b>83</b>

*X*

# List of Figures

1.1	Structure of Kir6.2 . . . . .	4
1.2	Structure of SUR1 . . . . .	5
1.3	K <sub>ATP</sub> architecture and nucleotide regulation . . . . .	8
1.4	SUR1 intrinsically modulates Kir6.2 . . . . .	9
1.5	Modes of regulation of K <sub>ATP</sub> . . . . .	10
3.1	Anap and TNP-nucleotides as FRET pairs . . . . .	25
3.2	TNP-nucleotides can bind with a similar pose to ATP . . . . .	28
3.3	ANAP incorporation . . . . .	36
3.4	Confocal imaging . . . . .	37
3.5	ANAP construct surface expression assay . . . . .	38
3.6	WT-GFP and W311*-GFP electrophysiology . . . . .	39
3.7	Unroofed membranes spectral images . . . . .	40
3.8	Unroofed membranes bleaching correction . . . . .	41
3.9	W311*-GFP unroofed membrane binding . . . . .	42
3.10	PCF bleaching correction . . . . .	43
3.11	ANAP is not quenched by ATP . . . . .	44
4.1	Systematic underestimation of single channel currents . . . . .	48
4.2	Simulated multibinomial currents . . . . .	50
4.3	Estimating open probability from stationary noise analysis . . . . .	51
4.4	Generating data from MWC model schemes . . . . .	52
4.5	Parameter retrieval from MWC models . . . . .	53
4.6	Parameter retrieval from MWC models . . . . .	54
5.1	G334D abolishes nucleotide binding at Kir6.2 . . . . .	60
5.2	C166S does not alter nucleotide binding . . . . .	62
5.3	C166S alters sensitivity to nucleotide inhibition . . . . .	68
5.4	C166S alters transduction of nucleotide binding to Kir6.2 . . . . .	69
6.1	SUR1 alters inhibition but not binding at Kir6.2 . . . . .	74
6.2	SUR1 associates with WT-GFP and W311*-GFP . . . . .	75
6.3	TMD0 and TMD0-LO associate with WT-GFP and W311*-GFP . . . . .	76
6.4	SUR1 alters inhibition but not binding . . . . .	78



# 1

## Introduction

### Contents

---

<b>1.1 General introduction</b>	2
<b>1.2 Pancreatic islets and the <math>\beta</math>-cell</b>	2
<b>1.3 Architecture of the pancreatic K<sub>ATP</sub> channel</b>	2
<b>1.4 Ligand-independent regulation of the pancreatic K<sub>ATP</sub> channel</b>	5
1.4.1 Assembly and trafficking	5
1.4.2 Regulation of intrinsic gating	7
<b>1.5 Ligand dependent regulation of the pancreatic K<sub>ATP</sub> channel</b>	7
1.5.1 Nucleotide regulation of the pancreatic K <sub>ATP</sub> channel	7
1.5.2 PIP <sub>2</sub> regulation of the pancreatic K <sub>ATP</sub> channel	10
1.5.3 Sulphonylurea regulation of the pancreatic K <sub>ATP</sub> channel	10
<b>1.6 Fluorescence methods in ion channel research</b>	10
1.6.1 Fluorescence as a tool	10
1.6.2 Forster resonance energy transfer	10
1.6.3 Unnatural amino acid incorporation	10
<b>1.7 Functional modelling of ion channels</b>	10
1.7.1 Why?	10
1.7.2 A model that fits	10

---

## 1.1 General introduction

## 1.2 Pancreatic islets and the $\beta$ -cell

Pancreatic islets are endocrine cells which are responsible for maintaining glucose homeostasis. There are roughly one million islets in a human pancreas, constituting 1-2% of the total pancreatic mass. Islets consist of three principal cell types; insulin secreting  $\beta$ -cells, glucagon secreting  $\alpha$ -cells and somatostatin secreting  $\delta$ -cells. Islets respond to increases in blood glucose by releasing insulin, which acts on peripheral tissues to increase glucose uptake and reduce blood glucose levels. Conversely, decreases in blood glucose leads to the release of glucagon, which acts on those tissues to stimulate glucose production and increase blood glucose.

## 1.3 Architecture of the pancreatic $K_{ATP}$ channel

ATP-sensitive potassium ( $K_{ATP}$ ) channels are present in many tissues, where they couple the metabolic state of a cell to its electrical activity by regulating the flow of  $K^+$  across the membrane.  $K_{ATP}$  channels are an octameric complex, comprised of four inwardly-rectifying potassium channel subunits (Kir6.1 or Kir6.2), each of which is associated with a sulphonylurea receptor subunit (SUR1, SUR2A or SUR2B). In pancreatic  $\beta$ -cells, the  $K_{ATP}$  channel isoform is composed of Kir6.2 and SUR1. Together, Kir6.2 and SUR1 form a complex nearly a megadalton in size and over 15 nanometres across (Figure 1.3A, 1.3B).

Inwardly-rectifying potassium channels are so named because they allow  $K^+$  to flow more easily into the cell than out of it (Figure 1.1A). This phenomenon is a consequence of voltage-dependent pore blockade by intracellular divalent cations (especially  $Mg^{2+}$ ) and polyamines. At depolarising membrane potentials, blockers are driven into the pore and  $K^+$  current is blocked, while at hyperpolarising potentials the blockers are cleared and  $K^+$  current can flow. Strongly rectifying Kir channels display drastically reduced conductance at potentials more positive

than the K<sup>+</sup> reversal potential. In contrast, Kir6.2 is a weak rectifier, and allows substantial current to flow at more positive potentials.


In addition to voltage, Kir6.2 is regulated by two endogenous ligands; phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) and adenine nucleotides (Figure 1.1B). The binding of adenine nucleotides to Kir6.2 leads to closure of the channel pore, while the binding of PIP<sub>2</sub> promotes the opening of the pore (Figure 1.1C). Activation by PIP<sub>2</sub> is a mechanism common to the whole Kir family, whereas inhibition by nucleotides is unique to the Kir6 subfamily.

SUR1 is a member of the ATP-binding cassette (ABC) family of transporters. While other ABC proteins transport substrate across the membrane, SUR1 does not appear to do so; instead it acts to modulate the function of its associated ion channel. The cystic fibrosis transmembrane conductance regulator (CFTR) is another member of the ABC family, and is an ion channel in its own right, capable of conducting chloride across the membrane. Like other ABC proteins, SUR1 contains two sets of transmembrane domains (TMD1 and TMD2) and two cytosolic nucleotide binding domains (NBD1 and NBD2). Unique to SUR is the presence of an additional transmembrane domain (TMD0) N-terminal to the core of the protein, and this domain forms the primary contact between SUR1 and Kir6.2.

The NBDs of ABC transporters are highly conserved, and consist of two subdomains: a larger RecA-like subdomain found in other P-loop ATPases, and a smaller  $\alpha$ -helical subdomain which is unique to ABC transporters. There are three key structural motifs present in these subdomains: the RecA-like subdomain contains the Walker A (W<sub>A</sub>) and B (W<sub>B</sub>) motifs, while the  $\alpha$ -helical subdomain contains the ABC signature motif (typically LSGQQ).


The two domains come together to form an antiparallel dimer with two nucleotide binding sites (NBS1 and NBS2) at the interface, such that NBS1 is formed from the W<sub>A</sub> and W<sub>B</sub> motifs of NBD1 and the signature motif from NBD2, whereas NBS2 is formed from the W<sub>A</sub> and W<sub>B</sub> motifs of NBD2 and the signature motif from NBD1. NBS2, also known as the consensus site as it is more similar in sequence to other ABC family members, is catalytically competent and able to hydrolyse ATP.

### 1.3. Architecture of the pancreatic $K_{ATP}$ channel



**FIGURE 1.1:** **A** Current-voltage plot demonstrating inward rectification of Kir channels. Here, the reversal potential of potassium ( $E_K$ ) is set to zero, i.e. there is an equal concentration of  $K^+$  on each side of the membrane. Weak rectifiers such as Kir6.2 exhibit only a weak voltage dependent decline in conductance (visualised as a departure from the dashed line of an ideal conductor). (Kind of adapted from Handbook of Ion Channels). **B** Cryo-EM structure of Kir6.2 (PDB #6BAA) captured with ATP bound (red) and with the proposed binding position of PIP<sub>2</sub> visualised by alignment of the channel with the X-ray structure of Kir2.2 solved in complex with a short-chain dioctanoyl (diC8) PIP<sub>2</sub> (PDB #6C3I). The plasma membrane is shown in pink. (Kind of adapted from Mike's JGP review). **C** Macroscopic currents from Kir6.2 channels coexpressed with SUR1 in excised patches from cultured cells, adapted from (Pratt/Shyng, 2011). Perfusion of ATP or PIP<sub>2</sub> is indicated by coloured bars, and demonstrates the contrasting effects of these two ligands on channel activity.

In contrast, NBS1 is the degenerate site, with a less conserved sequence and an inability to catalyse hydrolysis of ATP.



## 1.4 Ligand-independent regulation of the pancreatic K<sub>ATP</sub> channel

### 1.4.1 Assembly and trafficking

Biogenesis of K<sub>ATP</sub> channels occurs in the endoplasmic reticulum (ER), and is an important checkpoint in determining surface expression and channel stoichiometry [zerangue\_new\_1999-1, 5]. The precise nature of the events which occur between subunit translation and insertion of octameric K<sub>ATP</sub> into the cell membrane are not fully mapped out, but studies have highlighted some important quality control steps in this process which regulate K<sub>ATP</sub> channel expression. When Kir6.2 or SUR1 are expressed alone in heterologous systems, they are retained in the ER [zerangue\_new\_1999-1]. This mechanism is achieved through the exposure of a three amino acid ER-retention motif (RKR) in the cytoplasmic domains of both Kir6.2 and SUR1. Only upon complete assembly of the channel complex are the RKR motifs masked, allowing forward trafficking of K<sub>ATP</sub> to the cell surface. Deletion of the RKR motif [44], or mutation of the motif to AAA [zerangue\_new\_1999-1],

#### 1.4. Ligand-independent regulation of the pancreatic $K_{ATP}$ channel

results in unregulated surface expression of individual subunits and/or partially assembled channel complexes. Addition of a GFP label to the C-terminus of Kir6.2 is also sufficient to allow trafficking of subunits to the cell surface in the absence of SUR1 [john\_sulphonylurea\_1998-1].

In addition to the RKR motif, there are two N-linked glycosylation sites on SUR1 (N10 and N1050) which are required for cell surface expression [conti\_membrane\_2002]. Mutation of these sites to glutamines results in retention in the ER and drastically reduced expression of  $K_{ATP}$  on the cell surface. This mechanism is thought to be separate to that for the ER-retention motif, as mutation of RKR to AAA is not sufficient to drive surface expression of the glycosylation mutants [conti\_membrane\_2002].

A putative third site of trafficking regulation is in the C-terminus of SUR1. Mutation or deletion of a dileucine motif 16 amino acids distal to the C-terminal of SUR1 results in reduced surface expression of  $K_{ATP}$  channels in COSm6 cells [sharma\_c\_1999]. This reduction in expression is not rescued by C-terminal truncation of Kir6.2, indicating that this result is not due to masking of the RKR retention motif. The dileucines are therefore suggested to promote forward trafficking of assembled channel complexes to the cell membrane [sharma\_c\_1999]. Expression of  $K_{ATP}$  channels expressed in *Xenopus* oocytes is also dramatically reduced by truncation of the C-terminal 42 amino acids of SUR1 [vedovato\_role\_2018]. However, longer deletions of the SUR1 C-terminus did not reduce surface expression of channels in HEK293 cells [giblin\_cytoplasmic\_2002], and other modifications of the SUR1 C-terminus do not exhibit effects on surface expression [schwappach\_molecular\_2000]. The precise role of the dileucine motif remains unclear, and is potentially confounded by the use of expression system [giblin\_cytoplasmic\_2002, 5]

Failure of the channel complex to pass these three checkpoints results in ER-associated degradation (ERAD), a common pathway shared by most membrane and secretory proteins [bonifacino\_ubiquitin\_1998, yan\_role\_2005]. Both SUR1 and Kir6.2 are substrates for polyubiquitination, both when heterologously expressed and in INS-1 cells [yan\_role\_2005]. Application of proteasome inhibitors both


reduces the rate of degradation for Kir6.2 and SUR1, and increases the surface expression of K<sub>ATP</sub> channels by increasing their biogenesis efficiency [yan\_role\_2005].

The surface expression of K<sub>ATP</sub> channels is therefore controlled by a variety of different quality control mechanism to ensure that only correctly assembled octameric channel complex reach the cell membrane. Mutations which lead to defects in assembly and trafficking are therefore a common cause of congenital hyperinsulinemia (HI). These mutations are found throughout both Kir6.2 and SUR1, although they are more commonly found in SUR1 [5].


Interestingly, sulphonylureas are able to act as pharmacological chaperones and rescue surface expression of several mutations which would otherwise not traffic to the cell surface [yan\_sulfonylureas\_2004, yan\_sulfonylureas\_2006, yan\_congenital\_2007, yan\_congenital\_2007-2, martin\_pharmacological\_2016]. Sulphonylureas bind directly to the channel during biogenesis, as mutation of residues in SUR1 which are critical for sulphonylurea binding abolished or reduced the effectiveness of expression rescue [yan\_sulfonylureas\_2006]. Pharmacological chaperoning requires full assembly of the channel complex, as the presence of Kir6.2 was required to rescue expression of trafficking mutants even when the SUR1 RKR motif was mutated to AAA [yan\_sulfonylureas\_2006]. In addition, reducing the temperature at which cells are cultured can rescue some trafficking defects [yang\_low\_2005].

#### 1.4.2 Regulation of intrinsic gating

In the absence of nucleotides, K<sub>ATP</sub> channels are spontaneously active. Single K<sub>ATP</sub> channels exhibit bursts of brief openings, separated by long interburst closures [alekseev\_ligand-insensitive\_1998, babenko\_two\_1999, proks\_modeling\_2009, 24]. The intrinsic gating of K<sub>ATP</sub> can therefore be separated into two separate 'gating' processes; fast (responsible for intraburst closures) and slow (responsible for interburst closures). While it is helpful to distinguish between fast and slow gating processes to characterise channel kinetics and regulation, doing so does not require the existence of separate structural gates. When discussing channel gating



Fast gating is a property intrinsic to Kir6.2, and the intraburst mean closed time is unaffected by the presence of SUR1 [fang\_n-terminal\_2006]. In addition, the presence of nucleotides [alekseev\_ligand-insensitive\_1998, 24], or the presence of PIP<sub>2</sub>




**FIGURE 1.4:** **A** Single channel recordings of excised patches from cultured cells either expressing Kir6.2 alone with the C-terminal 36 amino acids truncated (Kir6.2 $\Delta$ C36) or coexpressing wild-type Kir6.2 with SUR1. Adapted from (Enkvetchakul/Nichols, 2000). **B** Single channel recordings of excised patches from cultured cells either expressing Kir6.2 $\Delta$ C36 alone or coexpressing Kir6.2 $\Delta$ C36 with the TMDO region of SUR1. Adapted from (Pratt/Shyng, 2011). In both panels, currents were recorded in symmetrical 140 mM K<sup>+</sup> at a membrane potential of -50 mV and openings are displayed as upward deflections. Note that the timescales differ slightly between panels as traces are from two separate papers. **C** Concentration-response relationship of ATP from macroscopic currents excised from *Xenopus* oocytes injected with either Kir6.2 $\Delta$ C26 mRNA alone (open circles), or a mixture of Kir6.2 $\Delta$ C26 and SUR1 mRNAs (closed circles). Response is given as the fraction of the slope conductance (G) remaining during exposure to ATP. Adapted from (Tucker/Ashcroft, 1997).

## 1.5 Ligand dependent regulation of the pancreatic K<sub>ATP</sub> channel

### 1.5.1 Nucleotide regulation of the pancreatic K<sub>ATP</sub> channel

While the binding of adenine nucleotides to the Kir6.2 binding site leads to closure of the pore, binding of nucleotides to either of the two NBSs of SUR1 in the presence of Mg<sup>2+</sup> activates the channel. The interplay between the action of nucleotides at



**FIGURE 1.5:** Adapted from [51]. The open-closed equilibrium of the  $K_{ATP}$  channel pore (denoted as  $L$ ) is energetically coupled to three different ligand binding sites. The four inhibitory nucleotide binding sites of Kir6.2 (labelled as NBS) bind either ATP or ADP (generalised to ANP) with an equilibrium binding constant  $K_A$ . The four stimulatory PIP<sub>2</sub> binding sites of Kir6.2 bind PIP<sub>2</sub> with an equilibrium binding constant  $K_B$ . The four stimulatory Mg-nucleotide binding site formed by the dimerisation of the NBDs of SUR1 (labelled as NBDs) bind either Mg-ATP or Mg-ADP (generalised to Mg-ANP) with an equilibrium binding constant  $K_C$ . Each binding domain interacts with the channel pore according to the factors  $D_A$ ,  $D_B$ , and  $D_{NBD}$  respectively. In addition, there is a potential coupling between the inhibitory nucleotide binding site of Kir6.2 and the stimulatory PIP<sub>2</sub> binding site of Kir6.2 described by the factor  $C$ .

these distinct sites (Figure 1.3C) determines the response of the  $K_{ATP}$  channel to metabolic changes, and therefore even subtle mutations or modifications to these sites can lead to diseases of insulin secretion.

In addition to its nucleotide binding and sensitivity to sulphonylureas, SUR1 also has intrinsic effects on channel properties. The presence of SUR1 increases the open probability of the channel pore (Figure 1.4A), and this increase is conferred by the TMD0 region (Figure 1.4B). Furthermore, coexpression of SUR1 increases the sensitivity of Kir6.2 to inhibition by nucleotides (Figure 1.4C).

**1.5.2 PIP<sub>2</sub> regulation of the pancreatic K<sub>ATP</sub> channel**

**1.5.3 Sulphonylurea regulation of the pancreatic K<sub>ATP</sub> channel**

**1.6 Fluorescence methods in ion channel research**

**1.6.1 Fluorescence as a tool**

**1.6.2 Forster resonance energy transfer**

**1.6.3 Unnatural amino acid incorporation**

**1.7 Functional modelling of ion channels**

**1.7.1 Why?**

**1.7.2 A model that fits**



# 2

## Methods

### Contents

---

2.1 Molecular biology . . . . .	11
2.2 Cell culture and channel expression . . . . .	12
2.3 Western blots . . . . .	13
2.4 Confocal microscopy . . . . .	14
2.5 Surface expression assays . . . . .	15
2.6 Epifluorescence imaging and spectroscopy . . . . .	16
2.7 Electrophysiology . . . . .	16
2.8 FRET calculations . . . . .	17
2.9 Unroofed binding measurements . . . . .	18
2.10 Patch-clamp fluorometry . . . . .	19
2.11 Data processing and presentation . . . . .	19
2.12 Computational docking . . . . .	20
2.13 Chemicals and stock solutions . . . . .	20

---

### 2.1 Molecular biology.

Human Kir6.2 and SUR1 were subcloned into pcDNA4/TO and pCGFP\_EU vectors for expression of wild-type and GFP-tagged constructs, respectively. pcDNA4/TO and pANAP were obtained from Addgene. peRF1-E55D and pCGFP\_EU were kind gifts from the Chin Laboratory (MRC Laboratory of Molecular Biology, Cambridge, UK) and the Gouaux Laboratory (Vollum Institute, Oregon, USA) respectively. Amber

stop codons and point mutations were introduced using the QuikChange XL system (Stratagene; San Diego, CA). All constructs were confirmed by DNA sequencing (DNA Sequencing and Services, University of Dundee, Scotland).

## 2.2 Cell culture and channel expression

HEK-293T cells were obtained from and verified/tested for mycoplasma by LGC standards (ATTC CRL-3216, Middlesex, UK). Our working stock tested negative for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (Lonza Bioscience; Burton on Trent, UK). Cells were plated onto either poly-L-lysine coated borosilicate glass coverslips (VWR International; Radnor, PA) or poly-D-lysine coated glass-bottomed FluoroDishes (FD35-PDL-100, World Precision Instruments). ANAP-tagged Kir6.2 constructs were labelled using amber stop codon suppression as described by Chatterjee et al. Transfections were carried out 24 hours after plating using TransIT-LT1 (Mirus Bio LLC; Madison, WI) at a ratio of 3 µl per µg of DNA. Unless specified otherwise, all transfections included a Kir6.2 construct with an amber stop codon (TAG) at position 311 (Kir6.2-W311<sup>TAG</sup>), SUR1, pANAP and eRF1-E55D in the ratio 0.5:1.5:1:1. Transfected cells cultured in Dulbecco's Modified Eagle Medium (Sigma; St. Louis, MO) + 10% foetal bovine serum, 100 U ml<sup>-1</sup> penicillin and 100 µg ml<sup>-1</sup> streptomycin (Thermo Fisher Scientific; Waltham, MA) supplemented with 20 mM ANAP (free acid, AsisChem; Waltham, MA). Cells were incubated at 33 °C and in the presence of 300 µM tolbutamide to enhance protein expression and channel trafficking to the plasma membrane. eRF1-E55D was included to increase efficiency of ANAP incorporation. Experiments were carried out 2-4 days after transfection. We also expressed constructs labelled with ANAP at positions I182, F183, F198, and I210. Kir6.2-F183\*, Kir6.2-F198\*, and Kir6.2-I210\* co-expressed with SUR1 did not produce sufficient currents for subsequent experimentation. Mutations at I182 are known to produce profound effects on nucleotide inhibition of K<sub>ATP</sub>. Thus, we did not consider this site for further experimentation.

## 2.3 Western blots

Transfected HEK-293T cells grown in 6-well plates were harvested in cold PBS (Life Technologies Limited; Paisley, UK), pelleted at 0.2 x g for 2.5 minutes and resuspended in lysis buffer containing 0.5% Triton X-100, 100 mM potassium acetate, and a cOmplete protease inhibitor tablet (1 tablet/50 ml, Roche; Basel, Switzerland), buffered to pH 7.4. After a 30-minute benzonase (Sigma) treatment at room temperature, samples were mixed with a DTT containing reducing agent and loading buffer (NuPAGE, Invitrogen; Carlsbad, CA) and run on a precast Bis-Tris 4-12% polyacrylamide gel at 200 V for 40 minutes. Proteins were wet transferred overnight onto polyvinylidene difluoride (PVDF) membranes (Immobilon P, Merck Millipore; Burlington, VT) in 25 mM Tris, 192 mM glycine, 20% methanol, and 0.1% SDS at 10 V on ice. Membranes were blocked with 5% milk in TBS-Tw (150 mM NaCl, 0.05% Tween 20, 25 mM Tris, pH 7.2) before staining for 30 minutes with a 1:1000 dilution of rat anti-HA monoclonal antibody in TBS-Tw (clone 3F10, Roche). After washing with TBS-Tw, membranes were incubated for 30 minutes with a 1:20,000 dilution of HRP-conjugated goat anti-rat polyclonal antibodies in TBS-Tw (Jackson ImmunoResearch; Ely, UK). Detection was performed using the SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher) and a C-DiGit Blot Scanner (Licor Biosciences; Lincoln, NE). Analysis was performed using custom code written in Python.

To confirm our ability to express full-length Kir6.2\*-GFP, we performed western blots for HA-tagged Kir6.2 constructs in detergent-solubilized HEK-293T cells (Figure 1—Figure supplement 1C). The HA tag plus a short linker (YAYMEKGITDLAYPYD-VPDY) was inserted in the extracellular region following helix M1 of Kir6.2 between L100 and A101. Transfection of wild-type Kir6.2-HA or Kir6.2-HA-GFP resulted in two bands on the western blots. The upper bands were close to the expected sizes for full-length Kir6.2-HA and Kir6.2-HA-GFP (46 kDa and 77 kDa, respectively).

We consistently observed a lower molecular weight band as well. This band must correspond to an N-terminally truncated Kir6.2 product, as the apparent molecular weight shifted with addition of the C-terminal GFP tag. Based on the

molecular weight, we predict that the truncated protein product initiated from a start codon in the first transmembrane domain. Therefore, we believe it is unlikely that this protein would form functional channels or traffic to the plasma membrane. When Kir6.2-W311<sup>TAG</sup>-HA or Kir6.2-W311<sup>TAG</sup>-HA-GFP were co-transfected with SUR1, pANAP, and eRF1-E55D, and cells were cultured in the presence of ANAP, the western blots were similar to wild-type Kir6.2-HA or Kir6.2-HA-GFP. Over 90% full-length Kir6.2\*-HA-GFP was produced under these conditions (Figure 1—Figure supplement 1D). We were unable to quantify the percentage of full-length Kir6.2\*-HA produced as the C-terminally truncated band resulting from termination at the TAG codon was very similar in size to the N-terminally truncated band. Co-expression with SUR1 increased the percentage of full-length Kir6.2\*-HA-GFP produced (Figure 1—Figure supplement 1D). In the absence of ANAP, we did not observe any full-length Kir6.2, indicating that there was no read-through of the amber (TAG) stop codon (Figure 1—Figure supplement 1D).

## 2.4 Confocal microscopy

Confocal imaging was performed using a spinning-disk system (Ultra-VIEW VoX, PerkinElmer; Waltham, MA) mounted on an IX81 microscope (Olympus; Southend-on-Sea, UK) with a Plan Apo 60x oil immersion objective (NA = 1.4), provided by the Micron Advanced Bioimaging Unit, Oxford. Transfected HEK-293T cells were incubated for 15 minutes with 1 nM CellMask Deep Red (Thermo Fisher) to stain plasma membranes before washing with PBS and imaging. ANAP was excited with a solid-state laser at 405 nM. GFP and CellMask were excited with an argon laser at 488 nM and 633 nM respectively. Images were captured on an EMCCD camera (ImagEM; Hamamatsu Photonics; Welwyn Garden City, UK) binned at 2 x 2 pixels and analysed using Python. A median filter with a box size of 32 x 32 pixels was applied to improve the signal-to-noise ratio by reducing background fluorescence.

We examined the surface expression of our ANAP-labelled constructs using confocal microscopy (Figure 1—Figure supplement 1A,B). When Kir6.2-W311<sup>TAG</sup>-GFP was co-transfected with SUR1 along with pANAP and eRF1-E55D in the presence

of ANAP, the ANAP and GFP fluorescence were co-localized at the plasma membrane. When wild-type Kir6.2-GFP was transfected under the same conditions, only GFP fluorescence was observed at the plasma membrane. ANAP fluorescence was diffuse and confined to the cytoplasm or intracellular structures. Thus, the plasma-membrane ANAP signal was specific for Kir6.2\*-GFP.

## 2.5 Surface expression assays

We measured surface expression of HA-tagged Kir6.2 subunits using an approach outlined by Zerangue et al. Cells were plated on 19 mm coverslips coated with poly-L-lysine and transfected as described above. Following incubation, cells were rinsed with PBS before fixation with 10% formalin for 30 minutes at room temperature. After washing again, cells were blocked with 1% BSA in PBS for 30 minutes at 4 °C before a 1-hour incubation at 4 °C with a 1:1000 dilution (in PBS) of rat anti-HA monoclonal antibodies. Cells were then washed 5 times on ice with 1% BSA in PBS followed by a 30-minute incubation at 4 °C with a 1:2000 dilution of HRP-conjugated goat anti-rat polyclonal antibodies. Cells were washed 5 times in PBS + 1% BSA and 4 times in PBS. Coverslips were removed from the culture dishes and placed in clean, untreated dishes for measurement. 300 µl of SuperSignal ELISA Femto Maximum Sensitivity Substrate (Thermo Fisher) was added to each sample and the luminescence was measured using a Glomax 20/20 Luminometer (Promega; Madison, WI) after a 10 second incubation.

HEK-293T cells were transfected with Kir6.2 constructs with or without a TAG stop codon corresponding to position 311. Cells were co-transfected with pANAP and eRF1-E55D in the presence or absence of SUR1 and cultured with or without ANAP. Wild-type Kir6.2-HA and Kir6.2-HA-GFP in the presence of SUR1 were included as positive controls. Kir6.2 constructs with no HA tag served as negative controls. In the presence of ANAP, we observed strong trafficking of Kir6.2\*-HA-GFP to the plasma membrane, but much less trafficking of Kir6.2\*-HA (Figure 1—Figure supplement 1E). When cells were cultured in the absence of ANAP, we observed little to no Kir6.2 surface expression from cells that were transfected with Kir6.2-W311<sup>TAG</sup>-HA

or Kir6.2-W311<sup>TAG</sup>-HA-GFP, suggesting that prematurely truncated constructs did not traffic to the plasma membrane. In the absence of SUR1, surface expression was weak for both wild-type and tagged constructs, despite the reported ability of Kir6.2-GFP to traffic to the plasma membrane in the absence of SUR1.

## **2.6 Epifluorescence imaging and spectroscopy**

Epifluorescence imaging and spectroscopy were performed using a Nikon Eclipse TE2000-U microscope with a 60x water immersion objective (Plan Apo VC, NA = 1.2, Nikon; Kingston upon Thames, UK) or a 100x oil immersion objective (Nikon, Apo TIRF, NA = 1.49). Imaging of ANAP was performed using a 385 nm LED source (ThorLabs; Newton, NJ) with a 390/18 nm band-pass excitation filter, an MD416 dichroic and a 479/40 nm band-pass emission filter (all from ThorLabs). GFP was imaged using a 490 nm LED source (ThorLabs) with a 480/40 nm band-pass excitation filter, a DM505 dichroic, and a 510 nm long-pass emission filter (all from Chroma; Bellows Falls, VT). Fluorescence spectra were collected by exciting ANAP as above but using a 400 nm long-pass emission filter (ThorLabs), then passing emitted light through an IsoPlane 160 Spectrometer (Princeton Instruments; Trenton, NJ) with a 300 g mm<sup>-1</sup> grating. Images were collected with 1 s exposures on a Pixis 400BR\_eXcelon CCD (Princeton Instruments).

## **2.7 Electrophysiology.**

Patch pipettes were pulled from thick-walled borosilicate glass capillaries (GC150F-15, Harvard Apparatus; Holliston, MA) to a resistance of 1.5 MΩ to 2.5 MΩ when filled with pipette solution. Currents were recorded at -60 mV from excised inside-out patches using an Axopatch 200B amplifier equipped with a Digidata 1322A digitizer and using pClamp 10 software (Molecular Devices; San Jose, CA). Currents were low-pass filtered at 5 kHz and digitized at 20 kHz. The bath solution (intracellular) contained 140 mM KCl, 10 mM HEPES, 1 mM EDTA and 1 mM EGTA (pH 7.3 with KOH). The pipette solution (extracellular) contained 140 mM KCl, 10 mM HEPES

and 1 mM EDTA (pH 7.4 with KOH). All experiments were carried out in Mg<sup>2+</sup>-free conditions. Currents were leak corrected using the current remaining in bath solution containing 5 mM barium acetate at 60 mV, assuming a linear leak with a reversal potential of 0 mV. Inhibition was calculated and corrected for rundown by alternating test concentrations of nucleotide solution with nucleotide-free solution, then expressing the test currents as a fraction of the average of the control currents before and after the test solution as described previously.

## 2.8 FRET calculations

We calculated the expected FRET efficiency between ANAP incorporated at amino acid position 311 and a docked TNP-ATP molecule as described previously. The equivalency between FRET efficiency (measured as ANAP quenching) and nucleotide binding is based on two main assumptions. Firstly, we assume that the observed quenching from a bound nucleotide does not differ dramatically between open and closed states of the channel. As there is no open-state structure of K<sub>ATP</sub>, we do not know exactly how much relative movement would occur between a bound TNP-ATP and Kir6.2-W311. However, based on cryo-EM structures of apo and nucleotide-bound Kir6.2 we do not expect to see a change in the distance between these two positions.

Secondly, we assume that the ANAP and TNP-ATP molecules on each subunit do not undergo energy transfer with those on other subunits to an extent which would dramatically change the observed quenching. At saturating TNP-ATP concentrations, where each ANAP-labelled site on Kir6.2 is occupied, FRET between ANAP and the closest acceptor will be kinetically favoured and the overall FRET efficiency will not be affected by cross-talk between neighbouring sites. In the limiting case, at low TNP-ATP concentrations, one would expect a large proportion of Kir6.2 tetramers (with four ANAP-labelled binding sites) bound to only a single TNP-ATP molecule. In this case, we expect a 4% overestimation of nucleotide binding as calculated using a numerical method to simulate a single TNP-ATP acceptor with multiple ANAP donors based on the distances calculated from our docking. This may have resulted

in our binding curves becoming artificially shallow at low concentrations. However, this difference is not significant in the context of our measurements as it is smaller than the observed error of our measurements at low TNP-ATP concentrations.

## 2.9 Unroofed binding measurements.

Unroofed membranes were prepared as described previously. A coverslip plated with transfected HEK-293T cells was removed from the culture media and rinsed with PBS. The coverslip was then briefly sonicated using a probe sonicator (Vibra-cell; Newtown, CT) leaving behind adherent plasma membrane fragments. Cells cultured on FluoroDishes were rinsed and sonicated directly in the dish. Unroofed membrane fragments were nearly invisible in bright-field images and identified by their GFP and ANAP fluorescence. Fluorescent TNP-nucleotides (Jena Bioscience; Jena, Germany) were diluted in bath solution and perfused onto unroofed membranes using a valve controlled microvolume superfusion system ( $\mu$ Flow, ALA Scientific Instruments; Farmingdale, NY).

Fluorescence spectra were collected as described above. A region of interest corresponding to the membrane fragment was manually selected and line-averaged for each wavelength. A similarly sized region of background was selected and averaged, then subtracted from the spectrum of interest. After subtraction, ANAP intensity was calculated by averaging the fluorescence intensity measured between 469.5 nm and 474.5 nm. Bleaching was corrected by fitting the normalised ANAP intensity of exposures taken during perfusion with nucleotide-free solution to a single exponential decay of the form

$$\frac{F}{F_{max}} = ae^{kt} + (1 - a) \quad (2.1)$$

then using the fit to correct the intensity of exposures taken during perfusion with test nucleotide solutions.

Some experiments were excluded from further analysis due to obvious cross-contamination between different solutions within the  $\mu$ Flow superfusion system.

These were identified by noticeable colour changes in the solution in the delivery tubes.

## 2.10 Patch-clamp fluorometry.

The tip of the patch pipette was centred on the slit of the spectrometer immediately after patch excision. Currents were measured as described above. Fluorescence emission spectra from the excised patch were acquired concurrently with current measurements, both during test solution application as well as nucleotide-free solution. Background subtraction was slightly imperfect due to the exclusion of TNP-ATP from volume of the glass of the pipette, resulting in spectra that have negative intensities at the TNP-ATP peak at high nucleotide concentrations. However, this over-subtraction does not affect the size of the ANAP peak, which we used to quantify nucleotide binding.

Some experiments were excluded from further analysis due to low fluorescence intensity, as we were concerned about a low signal to noise ratio influencing our results.

## 2.11 Data processing and presentation.

Raw spectrographic images and current traces were pre-processed in Python and Clampfit (Axon) before analysis with R. Where applicable, all experimental data points are displayed in each figure. The number of experiments is reported in the figure legends and tables. To help visualise uncertainty and prevent some data points being hidden, they are arranged with a small amount of horizontal jitter; vertical position remains unaffected. Unless otherwise stated, summary statistics are overlaid as the mean with error bars representing the standard error of the mean. Where these error bars are not visible, they are smaller than the size of the point used for the mean.

Hill fits to fluorescence quenching were nonlinear least-squares fits to the following equation:

$$\frac{y}{y_{max}} = 1 - E_{max} + \frac{E_{max}}{1 + 10^{(EC_{50}-[TNPATP]) \cdot h}} \quad (2.2)$$

where  $y$  represents normalised fluorescence intensity and  $EC_{50}$  and  $[TNPATP]$  are  $\log_{10}$  values. Current inhibition data were fit to the same equation but with  $y$  representing normalised current magnitude,  $IC_{50}$  instead of  $EC_{50}$ , and  $I_{max}$  instead of  $E_{max}$ .

## 2.12 Computational docking.

Computational docking of TNP-ATP into the nucleotide binding site of Kir6.2 was performed using AutoDock-Vina and Pymol (Schrödinger, LLC; New York, NY). 11 TNP-ATP structures from the Protein Data Bank (PDB accession #s 1I5D, 3AR7, 5NCQ, 5SVQ, 5XW6, 2GVD, 5A3S, 2PMK, and 3B5J) were used as starting poses and a 15x11.25x15 Å box was centred on the ATP bound to Kir6.2 in PDB accession #6BAA. Protonation states for each residue were assigned using PDB2PQR and PROPKA 3.0. The modal highest-scoring pose from the docking run was selected (PDB accession #5XW6) and distances were measured from a pseudo atom at the centre of the fluorescent moiety. TNP-ATP (PDB #3AR7) was positioned into the first nucleotide binding domain of SUR1 (PDB #6PZI) using the alignment tool in Pymol.

## 2.13 Chemicals and stock solutions.

Unless otherwise noted, all chemicals were obtained from Sigma. TNP-ATP was obtained as a 10 mM aqueous stock from Jena Bioscience and stored at  $-20^{\circ}\text{C}$ . 1 mM aqueous stocks of ANAP-TFA were prepared by dissolving the free acid in 30 mM NaOH, and were stored at  $-20^{\circ}\text{C}$ . Tolbutamide stocks (50 mM) were prepared in 100 mM KOH and stored at  $-20^{\circ}\text{C}$ .

# 3

## Measuring nucleotide binding to K<sub>ATP</sub>

### Contents

---

<b>3.1 Designing a nucleotide binding assay . . . . .</b>	<b>21</b>
3.1.1 Criteria for a useful assay for nucleotide binding to Kir6.2 . . . . .	21
3.1.2 Choosing a site to incorporate ANAP . . . . .	24
<b>3.2 Incorporating ANAP into the Kir6.2 binding site . . . . .</b>	<b>27</b>
3.2.1 Amber stop codon expression system . . . . .	27
3.2.2 ANAP incorporation into amber stop codon containing constructs . . . . .	27
<b>3.3 Testing for functional membrane expression . . . . .</b>	<b>29</b>
3.3.1 Surface expression of HA-epitope labelled Kir6.2 constructs . . . . .	29
3.3.2 Electrophysiology of Kir6.2 constructs . . . . .	30
3.3.3 Unroofed membrane binding assay of Kir6.2 constructs . . . . .	31
3.3.4 Patch-clamp fluorometry of Kir6.2 constructs . . . . .	33
<b>3.4 Discussion . . . . .</b>	<b>34</b>

---

### 3.1 Designing a nucleotide binding assay

#### 3.1.1 Criteria for a useful assay for nucleotide binding to Kir6.2

Previous approaches to measuring nucleotide binding directly to the different binding sites of K<sub>ATP</sub> have relied on isolating binding to individual classes of site by disrupting protein function; either by introducing mutations which abolish binding to a particular site, by measuring binding to Kir6.2 or SUR1 alone, or by measuring

binding to fragments of the two subunits.

Two key studies have attempted to measure nucleotide binding to the inhibitory site on Kir6.2 directly. The first relied on photoaffinity labelling of Kir6.2 by the radionucleotide 8-azido-[ $\gamma$ -<sup>32</sup>P]-ATP [1]. In these experiments, Kir6.2 with an N-terminal FLAG-tag was expressed in COS-7 cells, and membranes were separated by centrifugation. After incubating the membrane fractions with 8-azido-[ $\gamma$ -<sup>32</sup>P]-ATP, application of UV light results in a covalent linkage between the bound 8-azido-[ $\gamma$ -<sup>32</sup>P]-ATP and Kir6.2. After separation of the membrane fraction proteins on a gel, the quantity of bound radionucleotide can then be quantified by counting the radioactivity of the band corresponding to Kir6.2. These experiments were able to definitively establish that the inhibitory nucleotide binding site of K<sub>ATP</sub> was on Kir6.2, and suggested that the Kir6.2 binding site possessed a lower affinity toward the radionucleotide than the SUR1 binding sites.

The second made use of a fluorescent congener for ATP, trinitrophenyl (TNP)-ATP. TNP-ATP had previously been used in binding measurements of purified proteins due to its increased quantum yield (and thus increase in observed fluorescence) upon binding (need a ref). TNP-ATP is most commonly used as an antagonist of P2X receptors, which are also sensitive to endogenous ATP. The authors measured binding of TNP-ATP to the purified carboxyl terminal of Kir6.2 (residues 169 to 354) solubilised by linking it to mannose binding protein (MBP) [2]. The increased fluorescence of TNP-ATP when bound to the Kir6.2-MBP construct could be measured in a spectrometer, and allowed for equilibrium measurements of nucleotide binding. These experiments were able to establish an initial estimate for the binding affinity of the Kir6.2 site for TNP-ATP at 5  $\mu$ M. These findings were replicated in a similar study, which used fusion proteins constructed from residues 170 to 390 of Kir6.2 fused to glutathione-S-transferase (GST) and estimated a binding affinity of 5  $\mu$ M [[wang\\_inhibition\\_2006](#)].

These studies were hampered by the need to isolate the Kir6.2 binding site from the two SUR1 binding sites, which leads to unphysiological experimental conditions.

To improve on these methods, an ideal assay measuring nucleotide binding to the  $K_{ATP}$  channel needs to fulfill a number of criteria.

1. We need sufficient spatial sensitivity to distinguish between different classes of binding site; i.e. the assay should be capable of distinguishing binding to Kir6.2 from binding to NBS1 or NBS2.
2. We should be able to measure binding to a channel which we know is functional, so our experimental conditions cannot be drastically different from those used to measure channel function.
3. There should be minimal perturbation of the channel in order for binding measurements to be physiologically relevant.
4. For accurate measures of affinity, binding should be at equilibrium so we cannot use covalent interactions or other forms of non-equilibrium labelling.
5. We should be able to achieve a higher temporal resolution.

TO fulfill these criteria, we used an approach involving a fluorescent unnatural amino acid, ANAP. ANAP has been used increasing widely in the study of ion channel structure and function due to several desirable qualities.

1. It is smaller than traditional fluorescent labels such as fluorescent proteins or rhodamine derivatives. Therefore, it should be less perturbing to the function of the protein it labels.
2. As it is an amino acid, it can be site-specifically inserted into any protein. This avoids the issues of other small chemical dyes which are targeted to a site via post-translational covalent modifications, typically by reacting with a cysteine residue. While this can be avoided in some proteins by mutating each cysteine residue to an alternative residue to avoid off-target labelling, there are functionally important cysteines in the  $K_{ATP}$  channel which cannot be mutated. In addition, this does not solve the problem of off-target labelling of other membrane proteins

3. ANAP is environmentally sensitive, which has been used to great effect in other studies. Notably, the peak emission ranges from ~450nm to ~490nm depending on the hydrophobicity of the surrounding environment.


Initially, we hoped that the environmental sensitivity of ANAP fluorescence might be sufficient for the peak fluorescence of an ANAP residue inserted into an ATP binding site to measureably change when ATP was bound. Unfortunately, when we introduced ANAP directly into the Kir6.2 binding site in place of residues I182 or F183 we were not able to observe any functional  $K_{ATP}$  channels at the cell membrane.

Instead, we turned to FRET as a reporter for ATP binding. As ATP itself is not fluorescent, and has no intrinsic fluorescence quenching, we turned to TNP-ATP (Figure 3.1A). TNP-ATP is an excellent FRET partner of ANAP, as evidenced by the good overlap in the TNP emission spectra and the ANAP extinction spectra (Figure 3.1B). This leads to a theoretical distance-dependency of FRET which is most sensitive between 20 Å to 60 Å (Figure 3.1C) with a calculated R<sub>0</sub> of 38.4 Å.

### **3.1.2 Choosing a site to incorporate ANAP**

The theoretical R<sub>0</sub> of 38.4 Å for FRET between ANAP and TNP-ATP allowed for flexibility when choosing a site to incorporate ANAP. Ideally, a residue should be chosen to maximise the following aims:

1. The incorporated ANAP needs to be close enough to the nucleotide binding site of interest to report a quantifiable change in FRET when TNP-ATP is bound. This would not have to be close enough for 100 % FRET to occur, but the greater the efficiency achieved the higher the signal-to-noise ratio would be for measuring binding.
2. It also needs to be far enough from each other class of nucleotide binding site to avoid quenching by TNP-ATP bound to other sites.
3. In addition to avoiding interference from other classes of binding site, we also need to avoid cross-talk between nucleotide binding sites of the same



**FIGURE 3.1:** **A** Chemical structures of Anap and TNP-ATP shown with the fluorescent moieties highlighted in blue (Anap) or orange (TNP-ATP). **B** Normalised emission spectra (solid lines) of Anap (blue) and TNP-nucleotides (orange) overlayed on the normalised extinction spectra of Anap (filled light blue area). Extinction spectra were measured from Anap and TNP-nucleotides alone in aqueous solution. Anap emission is the averaged spectra from Kir6.2\* + SUR1 expressed in unroofed membranes. **C** Theoretical FRET efficiency displayed as a function of the distance between donor and acceptor fluorophores. The curve was calculated as a function of the overlap shown in **B**. The full formula is discussed in Chapter 2.

class on different subunits, as this would lead to difficulty interpreting the measured quenching. The ideal theoretical solution would be labelling only one nucleotide binding site per ion channel, but without using a concatemer this is not so easy in practise.

- More practically, incorporation of ANAP should not lead to drastic changes in nucleotide binding or channel gating properties, and the complete  $K_{ATP}$  channel needs to be expressed on the membrane.

To narrow down which residues could be candidates for ANAP incorporation to measure binding at Kir6.2, we took three cryo-EM structures of  $K_{ATP}$  with ATP bound

and computationally docked TNP-ATP into the nucleotide binding pocket (Figure 3.2). To assess the validity of computationally docking a ligand to each structure, we first attempted to dock ATP into the inhibitory binding pocket of Kir6.2 to check that the highest-scoring binding poses were similar to those observed in the cryo-EM structures. Docking ATP to both #6C3P and #6C3O yielded binding poses which were very similar to the pose found in the cryo-EM structures (Figures 3.2B, 3.2C). However, docking ATP to #6BAA resulted in binding poses which were in a flipped orientation relative to the pose found in the cryo-EM structure (Figure 3.2A).

We then took TNP-nucleotide structures from eleven different X-ray diffraction and cryo-EM structures published on RCSB to dock to the Kir6.2 binding site of K<sub>ATP</sub>. For both #6BAA and #6C3P we observed that the three highest scoring binding poses for TNP-nucleotides closely resemble those of the ATP solved in complex with the channel (Figures 3.2A, 3.2B). It is not so clear for #6C3O, for which the highest scoring poses are not in agreement with each other or the solved structure of ATP.

Based on the predicted TNP-ATP poses for #6BAA and #6C3P, we could narrow down potential ANAP incorporation sites to within 25 Å of the centre of the TNP-moiety, at which distance we would expect to see over 90 % FRET efficiency when TNP-ATP is bound to Kir6.2. In addition, we excluded residues which fell within 45 Å of NBS1 or NBS2, as this restricts the potential FRET between TNP-ATP bound at these sites and our chosen residue to roughly 25 % or less. While we can exclude residues which fall too close to the NBS's of SUR1, the close proximity of the Kir6.2 nucleotide binding sites to each other means that we cannot exclude intersubunit FRET occurring; i.e. TNP-ATP binding to a neighbouring subunit will also be able to quench ANAP to a certain extent. However, this occurs in a predictable way that we can measure and account for.

We ended up with one residue which fulfilled these criteria and for which membrane expression of the ANAP-incorporated channel could be detected: W311. It is a bulky hydrophobic residue similar to ANAP, and no mutations at this residue have been previously identified to alter K<sub>ATP</sub> function. To determine the extent to which crosstalk between neighbouring subunits would affect the measure FRET

efficiency when ANAP is incorporated at position 311, we simulated the expected FRET for a single  $K_{ATP}$  channel bound to 0-4 molecules of TNP-ATP in an idealised scenario with no crosstalk, and compared the observed fluorescence quenching to a scenario including the possibility of crosstalk (Figure 3.2F). Due to the much shorter fluorescence lifetime of TNP-ATP compared to ANAP, we observe a deviation from the ideal scenario. We can correct for this systematic deviation by transforming our observed ANAP quenching ( $F/F_{max}$ ) into  $\log_2(\frac{F}{F_{max}+1})$ .

## 3.2 Incorporating ANAP into the Kir6.2 binding site

### 3.2.1 Amber stop codon expression system


ANAP can be introduced into a protein of interest by essentially expanding the genetic code to incorporate a noncanonical amino acid. The amber stop codon (TAG) is the least frequently occurring stop codon in eukaryotic cells, and can be repurposed to encode ANAP. An orthologous set of tRNA and its aminoacyl-tRNA synthetase are mutated and screened through directed evolution in order to charge the tRNA which recognises the amber stop codon with ANAP. Thus, in cells expressing the ANAP charged tRNA, the amber stop codon introduced into the protein of interest is suppressed and ANAP is translated instead (Figure 3.3A).

### 3.2.2 ANAP incorporation into amber stop codon containing constructs

The nature of the amber stop codon suppression system requires a number of careful controls to ensure the following:

1. Stop codon recognition is not perfect, and there is a chance of read-through.  
Instead of incorporating ANAP, it is possible that the translation machinery can insert endogenous amino acids instead, leading to production of full length, unlabelled Kir6.2. However, we found that cells transfected with W311TAG constructs and pANAP which were not cultured in the presence of

### 3.2. Incorporating ANAP into the Kir6.2 binding site



**FIGURE 3.2:** A, B, C Cryo-EM binding poses for ATP bound to Kir6.2 (white) overlayed with either the ten highest scoring computationally docked ATP poses (red) or the three highest scoring computationally docked TNP-nucleotide poses (orange). Starting poses for ATP were generated from ten different random seeds based on the cryo-EM poses. Starting poses for TNP-nucleotides were generated from eleven structures taken from the RCSB database for different proteins solved in the presence of TNP-ATP. The poses shown are from #3B5J (X-ray diffraction structure of TNP-ADP bound to the NBD complex of a bacterial ABC transporter) and #5SVQ (X-ray diffraction structure of TNP-ATP bound to the human P2X3 ion channel). D Cryo-EM structure of the nucleotide binding site in the presence of ATP from #6C3P. E As D but with the three top scoring binding poses for docked TNP-nucleotides. F Correcting measured FRET efficiency for crosstalk between adjacent subunits requires transforming measured fluorescence quenching as described in the main text. Shown as a line is the idealised FRET efficiency for a single  $K_{ATP}$  channel bound to increasing numbers of TNP-ATP. Observed (blue) and corrected (orange) observed FRET efficiencies at each ligand occupancy state are shown as points.

ANAP did not produce full length Kir6.2 (Figure 3.3B, 3.3C), suggesting there is minimal read-through of the stop codon in our experiments.

2. Introducing a stop codon creates a risk that truncated Kir6.2 will be produced instead of ANAP labelled Kir6.2. This risk can be reduced by transfecting a dominant negative engineered version of eukaryotic translation termination

factor 1(eRF1-E55D), which does not efficiently terminate protein synthesis in response to the amber stop codon (but leaves opal and ochre stop codons nearly unaffected) and thus increases the incorporation of ANAP. We found that transfection of W311TAG constructs with a C-terminal GFP tag produced minimal truncated Kir6.2 (less than 10 % of the total density observed in Figure 3.3C).

3. Despite being the least frequent eukaryotic stop codon, the amber stop codon is still present in a significant number of protein sequences. We must be careful that ANAP is not incorporated into a protein which localises to the plasma membrane to an extent which would affect our ability to assign ANAP fluorescence to Kir6.2. We found that in cells transfected with GFP-tagged Kir6.2 without an amber stop codon, there was no increase in ANAP fluorescence at the cell membrane (Figure 3.4A, 3.4B). By contrast, when W311TAG-GFP was transfected, we saw a clear increase in ANAP fluorescence at the cell membrane (Figure 3.4C, 3.4D), suggesting that any observed ANAP fluorescence at the cell membrane originates from our labelled Kir6.2 construct.

### 3.3 Testing for functional membrane expression

#### 3.3.1 Surface expression of HA-epitope labelled Kir6.2 constructs

To assess the ability of ANAP-incorporating constructs to traffic to the plasma membrane, we used a luminescence-based surface expression assay. This assay relies on the recognition of an HA-epitope introduced into an extracellular region of the protein of interest (in this case, the N-terminal region of Kir6.2) by an anti-HA primary antibody followed by an HRP-conjugated secondary antibody. The luminescence after applying HRP substrate is then proportional to the amount of protein at the plasma membrane of the cells.

We assessed the membrane expression of N-terminally HA-tagged Kir6.2 (nHA-Kir6.2) in the presence or absence of ANAP in the culture media and in the presence

or absence of cotransfected SUR1. We also measured how the addition of a C-terminal GFP tag affected membrane expression under these conditions. We used untagged Kir6.2 as a control for nonspecific luminescence.

We find that for wild-type Kir6.2 (WT) there is roughly a 20-fold increase in observed luminescence when coexpressed with SUR1 over background, and roughly a 100-fold increase for the C-terminally GFP tagged Kir6.2 (WT-GFP, Figure 3.5A, 3.5C). There is no difference in surface expression of these constructs when ANAP is present in the culture medium (Figure 3.5A, 3.5D). When ANAP is incorporated at either residue 183 or 311 (F183\* and W311\* respectively) we see an increase in luminescence over background when coexpressed with SUR1 and with ANAP present in the culture medium (Figure 3.5A, 3.5C). The presence of the C-terminal GFP tag increases luminescence further for both constructs, dramatically so for W311\*. However, when F183\* is transfected and ANAP is not present in the culture media we still see a similar increase in fluorescence over background when compared to the luminescence when ANAP is present (Figure 3.5A, 3.5D), suggesting that a large proportion of the protein reaching the membrane does not have ANAP incorporated. In contrast, when W311\*-GFP is transfected with SUR1 in the presence of ANAP, we see a 10-fold increase in luminescence compared to when ANAP is not present, consistent with the majority of surface expressed protein incorporating ANAP. We also see a consistent increase in luminescence for all constructs aside from W311\* due to cotransfection with SUR1 (Figure 3.5B), suggesting that the incorporation of ANAP and the addition of a C-terminal GFP tag do not affect the role of SUR1 in forming the full K<sub>ATP</sub> complex and trafficking to the membrane.

### 3.3.2 Electrophysiology of Kir6.2 constructs

To establish whether W311\*-GFP formed K<sub>ATP</sub> channels with similar function to wild-type, we excised patches from cells transfected with either WT-GFP or W311\*-GFP cotransfected with SUR1. Excision was performed in Mg<sup>2+</sup>-free solution to reduce rundown and to prevent activation of the channel by nucleotides. We

observed similar magnitudes of current for both WT-GFP and W311\*-GFP, and currents ran own at similar rates.

We fit our inhibition data with equation 2.2 (Figure 3.6A) as described in the methods. Briefly, our fitting procedure assumes that there is a population parameter for  $IC_{50}$ ,  $I_{max}$  and  $h$ , and an additional 'random' effect on  $IC_{50}$  that can differ between experiments (shown in Figure 3.6C). Our fits result in posterior probability distributions for the population  $IC_{50}$  parameter shown in blue in Figure 3.6E. These distributions reflect our confidence in the population parameter for the  $IC_{50}$ , marginalising over the random effect of different experiments. For all  $IC_{50}$  and  $EC_{50}$  values fitted this way, in the text we will report the 95 % intervals of the posterior probability distribution for the fitted population parameter.

Perfusion of ATP resulted in current inhibition with an  $IC_{50}$  of 24  $\mu\text{M}$  to 45  $\mu\text{M}$  for WT-GFP+SUR1 and 75  $\mu\text{M}$  to 124  $\mu\text{M}$  for W311\*-GFP+SUR1. Thus, despite the distance from the ATP binding site, the incorporation of ANAP at W311 clearly affects some aspect of nucleotide inhibition. However, we assume that insights into the function of the ANAP-incorporating channel will still be applicable to wild-type channels despite the change in nucleotide inhibition.

Next, we established that TNP-ATP inhibits  $K_{ATP}$  (Figure 3.6B, 3.6D). We observed current inhibition with an  $IC_{50}$  of 0.7  $\mu\text{M}$  to 1.8  $\mu\text{M}$  for WT-GFP+SUR1 and 2.9  $\mu\text{M}$  to 10  $\mu\text{M}$  for W311\*-GFP+SUR1.  $K_{ATP}$  thus appears to be more sensitive to inhibition by TNP-ATP than by ATP. This could potentially be due to extra contacts made by the TNP moiety with Kir6.2, seen in our computational docking (Figure 3.2).

### 3.3.3 Unroofed membrane binding assay of Kir6.2 constructs

We then directly measured nucleotide binding to W311\*-GFP in unroofed membranes. Briefly sonicating transfected cells adhered to coverslips results in the lower membrane of the cell remaining stuck to the coverslip while the rest of the cell contents is disrupted and perfused away. This leaves the cytoplasmic domains of expressed  $K_{ATP}$  channels open to perfusion of TNP-ATP. These patches of membrane are barely visible under brightfield illumination, but due to the presence of the

### 3.3. Testing for functional membrane expression

C-terminal GFP tag and the incorporated ANAP, we can see patches of membrane expressing K<sub>ATP</sub> channels light up when we excite either fluorophore (Figure 3.7A). By measuring the fluorescence spectra of patches of unroofed membrane, we can separate the fluorescence emission peaks of the C-terminal GFP tag and the incorporated ANAP (Figure 3.7B). The peak at 472 nm corresponds to ANAP emission, while the peak at 508 nm corresponds to GFP emission. We observed no change in the locations of those peaks in the presence of ATP or TNP-ATP.

Perfusing TNP-ATP results in a decrease in the peak corresponding to ANAP fluorescence, and a concomittant increase in a fluorescence peak which corresponds to the TNP-ATP (Figure 3.7C). This phenomenon is the result of FRET between TNP-ATP bound to the channel at the Kir6.2 binding site. The decrease in ANAP fluorescence is almost directly correlated to an increase in bound nucleotide. We chose to measure the decrease in ANAP fluorescence rather than the increase in TNP-ATP fluorescence or the change in the ratio of ANAP:TNP-ATP fluorescence as we know that the ANAP fluorescence is specific to the Kir6.2 binding site. Increases in TNP-ATP fluorescence could in part be due to direct excitation of TNP-ATP bound to other membrane proteins. We can plot the quenching of ANAP fluorescence as a concentration-response curve as in Figure 3.7D.

Before analysis, ANAP bleaching was corrected as shown in Figure 3.8A. ANAP intensities of spectra imaged during bath perfusion in between applications of TNP-ATP were fit with Equation 2.1. We found that all unroofed experiments showed bleaching well described by the single exponential fit to equation 2.1. In each experiment, there was a mean proportion of 49 % ANAP fluorescence remaining by the last exposure (Figure 3.8C), maintaining a good signal-to-noise ratio for each spectra imaged.

To equivocate ANAP quenching and nucleotide binding, first we need to adjust for the FRET between adjacent subunits of Kir6.2. The difference between the ideal 1:1 subunit/ligand FRET efficiency and the simulated experimental FRET efficiency resulted in a correction factor of  $\log_2(\frac{F}{F_{max}} + 1)$ .

Secondly, we need to correct for incomplete FRET due to the distance between the donor and acceptor. Based on the computational docking, we predicted a maximal FRET efficiency of 91 % when every Kir6.2 subunit is bound by TNP-ATP. Fitting our adjusted data to a Hill equation results in a maximum observed FRET efficiency of 90 %, agreeing well with our prediction. We can then normalise our observed fluorescence data by this value.

Overall, these two corrections do not dramatically alter our results (Figure 3.9A), and we performed our analysis on both corrected and uncorrected results to ensure that there was no potential difference in interpretation which derived from treating our data in this way.

We observed quenching of ANAP fluorescence over a concentration range of TNP-ATP similar to the range in which we observed inhibition of current in W311\*-GFP (Figure 3.9B, 3.9C). When fit to a Hill equation, quenching ( $F/F_{max}$ ) was fit with an EC<sub>50</sub> of 21  $\mu\text{M}$  to 31  $\mu\text{M}$ , while the corrected binding data (adjusted  $F/F_{max}$ ) gave an EC<sub>50</sub> of 30  $\mu\text{M}$  to 45  $\mu\text{M}$ .

### 3.3.4 Patch-clamp fluorometry of Kir6.2 constructs

To ensure that the ANAP fluorescence we observe in the unroofed membranes is emitted by functional channels, we measured fluorescence quenching and current inhibition from the same excised patches (Figure 3.11A, 3.11B, 3.11C).

This experimental paradigm leads to two complications compared to performing the measurements separately. Firstly, the number of channels in an excised patch are far smaller than the number of channels in an unroofed membrane patch. This results in a much dimmer fluorescence readout, and a lower signal-to-noise ratio. Secondly, the presence of the pipette glass in the images results in some abnormalities in the background subtraction procedure. This is not due to the glass itself, but results from the occlusion of TNP-ATP from the image surrounding the patch. This leads to oversubtraction of the background TNP-ATP spectra, leading to an apparent negative peak in our corrected images. However, we find that there is no overlap of this peak and the ANAP peak, so our fluorescence quenching measurements are

unaffected by this phenomenon. We were able to correct for ANAP bleaching in the same manner as we did for unroofed membranes (Figure 3.10).

Our fluorescence measurements from excised patches are right-shifted when compared to our measurements for unroofed membranes (Figure 3.11D), with an  $EC_{50}$  value of  $76 \mu M$  to  $144 \mu M$ . Our finding that the  $EC_{50}$  for TNP-ATP binding is right-shifted compared to the  $IC_{50}$  for TNP-ATP inhibition is consistent between each experimental paradigm (Figure 3.11E). This finding has implications for how exactly the binding of nucleotides to Kir6.2 leads to closure of the  $K_{ATP}$  channel pore.


## 3.4 Discussion

We have demonstrated that we can measure nucleotide binding to the inhibitory nucleotide binding site of Kir6.2 in intact, functional  $K_{ATP}$  channels in their native membrane environment. Measuring binding directly in either unroofed membrane patches or in excised patches simultaneously with current recordings reveals that nucleotide binding is right-shifted compared to nucleotide inhibition; i.e.  $K_{ATP}$  channels begin to close at nucleotide concentrations where there is very little binding. This observation rules out certain models of ion channel function, which will be explored further in chapter ??.


These findings come with some important caveats. Firstly, the introduction of ANAP into Kir6.2 at residue 311 clearly impacts nucleotide inhibition of the channel, increasing the observed  $IC_{50}$  values for ATP. Our analysis of nucleotide binding and inhibition is therefore predicated on this decrease in sensitivity to ATP inhibition not reflecting a disruption of the normal physiological mechanism of ATP inhibition. As all of our binding experiments are performed in the W311\* background by necessity, we hope that measurements of relative changes in binding and inhibition will still be meaningfully interpretable as they will mirror similar relative changes in inhibition observed in the WT background.


Secondly,  $K_{ATP}$  channels are more sensitive to inhibition by TNP-ATP than by ATP. Again, this means that any conclusions we draw from experiments measuring relative changes in binding and inhibition rely on those relative changes affecting


ATP binding and inhibition to a similar extent. To try and ameliorate these caveats as best as we can, where possible we have performed control experiments in the WT background with ATP to ensure that introduced mutations result in similar relative effects on nucleotide inhibition despite the background of the construct or the identity of the nucleotide. As control experiments of this sort are not possible in unroofed membranes, where it is impossible to measure current inhibition, we have focused on patch-clamp fluorometry for constructs where expression is good enough to measure sufficient fluorescence.




**FIGURE 3.3:** A ANAP incorporation is accomplished through the transfection of two plasmids. pANAP codes for tRNA (red) and its tRNA synthetase (green), while pW311TAG codes for Kir6.2 with an amber stop codon (TAG) inserted in place of the codon for W311 (grey). When the transfected cells are incubated with ANAP (present here as its free acid, ANAP-TFA, blue) the tRNA synthetase assembles tRNA which is capable of recognising the amber stop codon and loads it with ANAP. During translation of W311TAG, the primed ANAP tRNAs recognise the TAG and insert ANAP into the desired location. B Two separate western blots against the N-terminal HA epitope incorporated into WT or W311\* (left) and WT-GFP or W311\*-GFP (right) constructs. Cells were co-transfected with pANAP, eRF1-E55D, and SUR1 unless otherwise indicated. Full-length Kir6.2 constructs are indicated on each gel with a dashed box. The doublets represent an N-terminally truncated product described in the main text. C Each lane from the gel containing C-terminally GFP-tagged constructs is displayed normalised to its highest intensity accompanied by the line averaged density trace. The density peak corresponding to full-length Kir6.2 is filled in blue. The density peak for C-terminally truncated Kir6.2 is filled in orange.












**FIGURE 3.7:** **A** An unroofed membrane patch imaged either with brightfield illumination (top panel), GFP fluorescence (middle panel) or ANAP fluorescence (bottom panel). The dashed white lines indicate the region of the image isolated by the spectrometer mask for spectral imaging. **B** Bleaching-corrected spectral images of the unroofed membrane patch in **A** captured in the presence of different concentrations of TNP-ATP. Each image represents the region delineated by the dashed white lines in **A**, but the  $x$ -dimension is lost and instead we are able to separate the emitted light by wavelength. **C** Line-averaged, bleaching-corrected traces of the spectral images in **B** coloured according to the TNP-ATP concentration present. The two clearest peaks in emission belong to ANAP and GFP. The ANAP peak is marked with a grey line. At the higher TNP-ATP concentrations, the presence of a third peak belonging to the TNP-moiety begins to appear as the ANAP peak reduces in intensity due to FRET. **D** Bleaching-corrected ANAP fluorescence intensities of the spectral traces in **B** expressed as the average fluorescence of the ANAP peak (the average intensity of the spectra inside the grey line in **B**) divided by the average fluorescence of the ANAP peak in 0 TNP-ATP, or  $F/F_{max}$ .






**FIGURE 3.9:** A Fluorescence quenching of W311\*-GFP+SUR1 by TNP-ATP in unroofed membrane patches. Each uncorrected point (white with dashed blue outline) represents an individual measurement normalised to the maximum current observed in that unroofed membrane. Each corrected point (blue filled points) has been transformed to  $\log_2(\frac{F}{F_{\max}} + 1)$ . The smooth filled curves are the 95 % intervals of the posterior probability distribution of fits to equation 2.2 as described in the methods. The dashed curve is the median of the fits to the uncorrected data. B Posterior probability distribution for the population  $EC_{50}$  values from fits to the corrected  $F/F_{\max}$  data. C Data from each experiment is shown separately. The smooth filled curves are the 95 % intervals of the posterior predictions for each experiment.



### 3.4. Discussion



# 4

## MWC modelling

### Contents

---

<b>4.1 Modelling of ion channel function . . . . .</b>	<b>45</b>
4.1.1 Restricting the subset of possible models . . . . .	45
4.1.2 Considerations for fitting a model . . . . .	45
4.1.3 Determining open probability . . . . .	45
<b>4.2 Implementing an MWC model . . . . .</b>	<b>50</b>
4.2.1 A simple case . . . . .	50
4.2.2 The role of PIP <sub>2</sub> . . . . .	50

---

### 4.1 Modelling of ion channel function

#### 4.1.1 Restricting the subset of possible models

#### 4.1.2 Considerations for fitting a model

#### 4.1.3 Determining open probability

Noise analysis - you can get a correct answer the wrong way (Puljung).

Measuring the open probability of an ion channel is most accurately accomplished by single-channel electrophysiological recordings, which allows direct measurement of the time a channel spends in an open state. This approach does not allow for the determination of the open probability of a population of channels

great than 2/3 at a time, as it becomes increasingly difficult to separate the openings of different channels in the population. Thus it would not be possible to determine single channel open probability simultaneously with nucleotide binding, as the fluorescence signal from a small number of channels would be impossible to resolve.

Another approach is noise analysis of currents from large populations of channels. The 'noise' in noise analysis refers to current fluctuations which occur when recording from a population of ion channels due to the stochastic channel gating of individual channels. If there are a constant number of channels ( $N$ ) which are gated independently from each other and share a homogenous open probability ( $P_O$ ) and a single open conductance level ( $i$ ), the observed macroscopic current level  $I$  can be described by equation 4.1:

$$I = iNP_O \quad (4.1)$$

and the observed variance of the macroscopic current can be described by the variance of the binomial distribution, equation 4.2:

$$\sigma^2 = NP_O \cdot (1 - P_O) \cdot i^2 \quad (4.2)$$

where the single channel current is essentially a scaling factor. If we assume that in a given recording  $N$  and  $i$  remain constant, and it is  $P_O$  which changes in response to any given stimuli, then we can combine equations 4.1 and 4.2 to yield equation 4.3:

$$\sigma^2 = iI - \frac{1}{N} \cdot I^2 \quad (4.3)$$

This equation yields a parabola from  $I = 0$  to  $I = Ni$ . Intuitively, there can be no variance when  $P_O$  is exactly 0 or 1, as there will be no opening or closing events which can give rise to current fluctuations. Once  $i$  and  $N$  have been determined for a given experiment, the observed current magnitude  $I$  can be converted into the  $P_O$  for the population of channels by rearranging equation 4.1 as follows:

$$P_O = \frac{I}{iN} \quad (4.4)$$


Equation 4.3 can be fit to experimental data by calculating the variance of observed current at different current magnitudes. This calculation is not exactly

trivial, and has been accomplished a number of different ways for different purposes. For channels with fast inactivation such as the  $\text{Na}_v$  family, non-stationary noise analysis involves repeating a stimulus multiple times and measuring variance as the squared sum of deviations from the mean of the current magnitude calculated at the same time point across multiple stimuli, referred to in the literature as an 'isochrone'. For channels which do not inactivate, stationary noise analysis is possible, and variance can be measured as the squared sum of deviations from the mean current magnitude over a period of time for which  $I$  is 'stationary' (Figure 4.1A, 4.1B, 4.1C).

Stationary noise analysis has been described for  $\text{K}_{\text{ATP}}$  channels before by a number of different researchers (Shyng, Paolo, Peter). Unfortunately, in most of the published research the exact procedure for extracting the parameters in equation 4.2 is described in the methods section, but the quality of the fits and the value of the fitted parameters besides the final calculated  $P_O$  is not discussed. A notable exception to this rule is (Paolo), in which two findings are discussed. Firstly, fitting equation 4.3 to the mean and variance of 200 ms sections of macroscopic currents from wild-type Kir6.2+SUR2A resulted in a systematic underestimation of the single channel current  $i$ . From single channel experiments, the single channel current was determined to be 4 pA, while the value obtained from fitting macroscopic currents was only 2 pA. In the case of WT-GFP+SUR1, we see a similar underestimation of single channel current (Figure 4.1D, 4.1E, 4.1F), with fits yielding estimates of 1.66 pA to 2.64 pA, while measured single channel currents are at least 4 pA. This underestimate of  $i$  is most likely due to an underestimate of channel current variance as  $P_O$  increases, which could be due to two main reasons.

Firstly, the process of filtering and digitising channel currents can lead to underestimates of variance depending on the relationship between the open time of the measured channel and the cut-off frequency of the filter used. It is unlikely that this phenomenon is responsible for our findings, as the  $\text{K}_{\text{ATP}}$  mean open time duration is close to 1 ms and filtering at 5 kHz would lead to less than a 5 % underestimation of  $i$ . Even if the mean open time of WT-GFP+SUR1 was closer to 0.1 ms, we would expect a 20 % reduction rather than the 50 % we actually observe. Empirically, we

can use the frequency power spectrum of our measured current fluctuations to determine whether there may be high frequency channel openings we are missing (Figure 4.1G). For WT-GFP+SUR1, we observe that at frequencies approaching our filter cut-off at 5 kHz there is very little observed amplitude in active channels when compared to fully inhibited channels, suggesting we are not missing high frequency current fluctuations.




Secondly, an underestimation of  $i$  could occur due to violations in the underlying assumptions of the binomial distribution. The first two assumptions are that  $N$  and  $i$  are constant throughout a recording. We know that  $i$  does not change on nucleotide inhibition of  $K_{ATP}$  channels, nor is it affected by  $PIP_2$  and rundown. Additionally, in excised patches it is improbable that there will be any change in  $N$  during the course of a recording. The third assumption is that the channels in a patch share a homogenous  $P_O$ , which exhibits graded changes in response to stimuli (in our case, application of nucleotide). This assumption is far harder to justify for our experimental condition, in which channel rundown due to loss of  $PIP_2$  results in a complicated mixture of channel populations with different  $P_O$ s.

An extreme case in which channels transition between two states, one where  $0 < P_O < 1$  and one where  $P_O \approx 0$  can be approximated by equation 4.2, with a channel transitioning to the  $P_O \approx 0$  state essentially considered to be no longer available to open, thus reducing  $N$ . Thus, fitting the observed current-variance data with 4.2 would yield a straight line where the slope of the line is equal to  $i \cdot (1 - P_O)$ . This formulation of equation 4.2 has been used successfully in the analysis of currents from CRAC channels, VSOA channels, and in the analysis of a specific cardiac  $K_{ATP}$  channel mutation. Unfortunately, in our case channel rundown does not render the  $K_{ATP}$  channel completely unable to open, with fully rundown channels displaying single channel open probabilities in the range of 0.05 to 0.25. Instead of each current measurement being a draw from a single binomial distribution, we are instead drawing from a mixture of binomial distributions with different  $P_O$ s. We can demonstrate how this leads to an underestimation of  $i$  by simulating a simple case where there are two populations of channels,  $a$  and  $b$ , one with a tenfold lower  $P_O$  than the other.

$$N_a + N_b = 1000$$

$$0 < P_{O_a} < 1 \quad (4.5)$$

$$P_{O_b} = \frac{P_{O_a}}{10}$$




## 4.2 Implementing an MWC model

### 4.2.1 A simple case

The simplest case of an allosteric MWC model for an ion channel is shown as Scheme I in Figure 4.4A. This simple case assumes a channel composed of a single monomer with a single binding site for ligand *A*. The channel is restricted to two states, open and closed. These two states exist in an equilibrium described by *L*, which is equivalent to  $\frac{[\text{open}]}{[\text{closed}]}$ . Ligand *A* binds to the protein with a microscopic affinity constant  $K_A$ . The ligand *A* differentially stabilises the open and closed states by a constant  $D$ . When  $D$  is unity, the ligand *A* binds equally to both states and so does not influence the conformational changes of the channel. When  $D > 1$ , the ligand *A* preferentially stabilises the open state, while when  $D < 1$  the ligand instead preferentially stabilises the closed state.


### 4.2.2 The role of PIP<sub>2</sub>

If we consider introducing a second ligand *B* which binds to a distinct site on the same monomer and does not directly interact with ligand *A*, we introduce the states shown in Scheme II of Figure 4.4A. Each ligand has its own microscopic association constant ( $K_A$  or  $K_B$ ) and its own preference for the open or closed states ( $D_A$  or  $D_B$ ). Importantly, there is no interaction term between ligand *A* and ligand *B*; the only way the binding of the ligands can impact each other is through effects on *L*. Scheme II is therefore a restricted form of scheme III, which explicitly introduces




a term for local interaction ( $C$ ) between binding sites for ligands  $A$  and  $B$  on the same monomer. When  $C$  is unity, Scheme III becomes Scheme II. When  $C < 1$ , binding of one ligand reduces the ability of the other ligand to bind on the same monomer. When  $C > 1$ , binding of one ligand enhances the ability of the other ligand to bind on the same monomer.

To study nucleotide binding to Kir6.2, I have used Scheme I (expanded to incorporate four identical monomers) as an approximation of the K<sub>ATP</sub> channel, with ligand  $A$  representing nucleotides. To determine whether this approximation is



appropriate, I generated data using each of the three schemes as the underlying model of channel function and then fit the generated observations to Scheme I (Figure 4.4B, 4.4C, 4.4D). Ten individual sets of observations were generated using the inputs shown above each figure panel as the centre of a lognormal distribution with a standard deviation of 0.25. These observations were then fit to Scheme I (as done previously throughout the thesis) and the values of the three free parameters ( $K_A$ ,  $D_A$  and  $L$ ) were estimated (Figure 4.4E).

We know that Scheme I is only an approximation of nucleotide binding as it




does not explicitly include PIP<sub>2</sub>. The question is, if the underlying data generating model is Scheme II which explicitly includes a second ligand, are we still able to extract meaningful parameter estimates by fitting the observed data to Scheme I? In addition, to date it remains unclear whether there is local allosteric between the nucleotide and PIP<sub>2</sub> binding sites. The existence of local allosteric would mean that Scheme III, which includes an explicit term for this interaction, would best represent the true data generating model. We can show that even when Scheme II or Scheme III are the underlying data generating model, with ligand *B* representing PIP<sub>2</sub>, we are still able to extract the true values of  $K_A$  and  $D_A$  by fitting the generated data to Scheme I (Figure 4.4). Parameter choices for Scheme II and III are such that the open probability of the channel at 0 [ATP] is still 50%, equivalent to  $L = 1$  in Scheme I. I really need to redo this with the true  $L$  set to 0.01 instead of 0.1 as that is closer to post rundown open probability...

We can also show that when Scheme I is the underlying data generating model, changes in any of the three parameters are easily identified and retrieved by fitting

the observed data to Scheme I (Figure 4.5). This suggests that introducing mutations which directly effect any of the three parameters of this model would be easily identifiable if Scheme I was the true underlying model.

What if Scheme II or III were the underlying model? We would still expect changes in the three parameters which exist in Scheme I to be identifiable (I should probably check this), although  $L$  would not represent the true unliganded open/closed equilibrium as we would be estimating an  $L$  modified by the resting PIP<sub>2</sub> concentration,  $K_B$ ,  $D_A$  and  $C$  - in this case, the estimated  $L$  parameter in fact represents the ATP-unbound open/closed equilibrium.



**FIGURE 4.6:** **A, B** Data generated from **A** Scheme II or **B** with  $K_B$  shifted from  $10^5$  to  $10^6$ .

However, it is unclear how changes in parameters which are not explicitly modelled in Scheme I will affect the generated data and the parameter estimates obtained by fitting the data to Scheme I. Figure 4.6 shows the results of increasing  $K_B$  by tenfold on data generated from Scheme II (Figure 4.6A) or Scheme III (Figure 4.6B). The first observation of note is that the generated data closely resemble those generated from Scheme I when  $L$  is increased (Figure 4.5C), and indeed when the  $L$

parameter estimates for a tenfold shift in  $K_B$  in Scheme II/III and tenfold shift in  $L$  for Scheme I are compared (Figure 4.6C, right panel) are compared they appear to be similar. So far so good, as an observed increase in  $L$  when fit with Scheme I would lead us to draw the correct inferences about changes in the underlying model (i.e. the open probability of the cnall has indeed increased). However, changes in  $K_B$  are not perfectly captured by changes in  $L$  when fit to scheme I. Notably, if local allosteric exists between the nucleotide and PIP<sub>2</sub> binding site - if Scheme III is the true underlying model - then fitting the observed data to Scheme I would lead us to estimate an incorrect value for  $K_A$  (Figure 4.6A). Thus, if there is local allosteric between the sites, then a mutation which induces an increase in the binding affinity for PIP<sub>2</sub> would not just increase our estimate of  $L$  (which would lead to a correct inference) but it would also decrease our estimate of  $K_A$  by a not-insignificant amount, which could lead to the incorrect inference that a mutation is causing a direct change in nucleotide binding when it is in fact causing a direct change in PIP<sub>2</sub> binding, which through local allosteric is influencing our estimates of  $K_A$ .



# 5

## Nucleotide regulation of Kir6.2

### Contents

---

5.1	Introduction	57
5.2	Nucleotide binding	59
5.2.1	G334D abolishes nucleotide binding	59
5.3	Channel gating	61
5.3.1	C166S alters inhibition without affecting binding	61
5.3.2	Mutations at E179 alter both inhibition and binding	63
5.3.3	Mutations at K39 alter both inhibition and binding	66
5.4	Discussion	67

---

### 5.1 Introduction

There are variety of ways in which mutations can lead to altered  $K_{ATP}$  channel function. These can be divided into two broad categories; mutations which have a ligand-independent effect, and those which affect the ligand-dependent functions of the channel. Each of these categories can be further subdivided. Mutations which exhibit ligand-independent effects do so via two major mechanistic routes. Firstly, mutations can affect channel production, trafficking, and more generally expression of  $K_{ATP}$  at the cell membrane [3–5]. Secondly, mutations can lead to alterations in the open-closed equilibrium of the channel (i.e. by altering  $L$  in Figure ??). Reductions

in the stability of the open state leads to decreased intrinsic  $P_O$  [6–9], while increases in open state stability leads to increased intrinsic  $P_O$  [43].

Reduction in activity can be caused by either reductions in stability of the open state of the channel (i.e. a reduction in the resting  $P_O$ ) [9]), or reductions in the ability of  $Mg^{2+}$ -nucleotides or  $PIP_2$  to stimulate channel currents [10–12]. Inactivating mutations *in vivo* result in hyperinsulinism (HI), with the reduction in  $K_{ATP}$  channel activity leading to persistent depolarisation of pancreatic  $\beta$ -cells and permanently increased insulin secretion [13, 15].

Activating mutations cause gain of function by increasing the intrinsic stability of the open state of the channel, by reducing the sensitivity of the channel to inhibition by nucleotides, or both. Mutations which increase the intrinsic stability of the open state result in an increase in the resting  $P_O$  of the channel. A distinction then has to be made between the apparent nucleotide affinity of the channel

It is possible to reduce sensitivity to ATP inhibition by two separate mechanistic routes.

The wide variety of  $K_{ATP}$  channel mutations, their functional effects and their involvement in diseases of insulin secretion are detailed across extensive reviews: [14–22]

Electrophysiological characterisation of  $K_{ATP}$  mutations tend to assign one of two roles to individual residues on Kir6.2. Firstly, if a change in the  $IC_{50}$  value for nucleotide inhibition is observed in the absence of a change in intrinsic (or nucleotide-independent) gating, typically measured as a change in single channel open probability (although thorough studies also tend to examine the bursting characteristics of the channel), then the residue is assumed to form part of the inhibitory nucleotide binding site but not affect transduction of binding to the channel pore. Secondly, if a change in the  $IC_{50}$  value for nucleotide inhibition is observed in addition to a change in intrinsic gating, the residue is assumed to regulate the relative stability of the closed and open states of the channel. The effects on nucleotide inhibition are taken to secondary to this main effect, due to the established preference of nucleotides for the closed state. Further interrogation of


residues in this second category is very difficult using electrophysiological measures alone, as without measuring binding of nucleotides directly it is impossible to truly separate effects on open probability from effects on binding and transduction. In this chapter, we aim to clarify the role of several residues implicated in regulating the inhibitory effect of nucleotides on Kir6.2 by measuring TNP-ATP binding directly to the inhibitory nucleotide binding site, where possible in conjunction with simultaneous current measurements.

## 5.2 Nucleotide binding

### 5.2.1 G334D abolishes nucleotide binding

Residue G334 of Kir6.2 is located in the C-terminal region (Figure 5.1) and has been hypothesised to form part of the ATP binding site since electrophysiological studies demonstrated a dramatic reduction in nucleotide sensitivity upon mutation of the residue [23–25]. In addition, mutation of this residue to aspartic acid (G334D) results in severe permanent neonatal diabetes mellitus [26]. This hypothesis was confirmed by the solving of cryo-EM structures of K<sub>ATP</sub> in the presence of ATP, which revealed the close proximity of residue G334 to the bound ATP [27–30]. Mutating G334 to a total of 13 different amino acid substitutions led to a increase in the IC<sub>50</sub> for ATP by over an order of magnitude in excised patches [25]. However, only two of those substitutions (R and K) resulted in any changes in nucleotide-independent channel gating when examined at the single-channel level, with unliganded  $P_o$  remaining constant. It has therefore been suggested that while G334 forms part of the ATP binding site of Kir6.2, it does not participate in channel gating or transduction of ligand binding to the channel pore.

We sought to test this directly by measuring the binding of TNP-ATP in unroofed membranes to W311\*,G334D-GFP+SUR1. Fluorescence spectra captured from unroofed membrane patches expressing W311\*,G334D-GFP+SUR1 were indistinguishable from those expressing W311\*-GFP+SUR1. The location of the ANAP peak and the bleaching characteristics were also identical. We found that ANAP fluorescence from



**FIGURE 5.1:** A Residue G334 is shown in green in the cryo-EM structure of Kir6.2 (yellow, PDB #6BAA). Docked TNP-ATP is shown as sticks in red. B Fluorescence quenching of W311\*,G334D-GFP+SUR1 by TNP-ATP in unroofed membrane patches. Each point represents an individual experiment. The smooth filled curves are the 95 % intervals of the posterior probability distribution of fits to equation 2.2 as described in the methods. C Data from each experiment is shown separately. The smooth filled curves are the 95 % intervals of the posterior predictions for each experiment. D Posterior probability distributions for the estimated population  $EC_{50}$  values are shown coloured according to their intervals.

W311\*,G334D-GFP+SUR1 was barely quenched by even 1 mM TNP-ATP, reducing the apparent binding  $EC_{50}$  from 30  $\mu$ M to 45  $\mu$ M to at least 2.8 mM. Unfortunately, we were unable to resolve macroscopic currents from W311\*,G334D-GFP+SUR1 in excised patches despite seeing fluorescence in unroofed membranes. Thus, we were unable to measure nucleotide inhibition of this construct to determine whether the

G334D substitution affected transduction in addition to this binding effect.


## 5.3 Channel gating

### 5.3.1 C166S alters inhibition without affecting binding

Residue C166 of Kir6.2 is located at the cytosolic end of the second transmembrane domain (Figure 5.2A, [27–30]), and has been suggested to play a role in regulating the intrinsic gating of the channel [31–36]. Mutations at this residue lead to dramatically increased unliganded  $P_O$  in single-channel experiments [32, 33, 36], and a reduction in sensitivity to nucleotide inhibition at both single-channel and the macroscopic level [32–34, 36, 37]. In addition, two substitutions at this residue (F and Y) have been found to cause severe neonatal diabetes [31]. Electrophysiological measurements alone are not sufficient to distinguish between the reduction in sensitivity to nucleotide inhibition being caused by the increase in intrinsic  $P_O$  alone, or whether there is an additional disregulation of transduction.

We measured TNP-ATP binding to W311\*,C166S-GFP+SUR1 in unroofed membranes to determine the how mutations at C166 reduce sensitivity to nucleotide inhibition (Figure ??). We observed no real change in binding of TNP-ATP to the channel, with an EC<sub>50</sub> of 44 μM to 74 μM. If the C166S mutation solely increases the  $P_O$  of the channel, we would expect an increase in the apparent EC<sub>50</sub> of nucleotide binding due to the preference of nucleotides for the closed state of the channel. This finding suggested a role for C166 in the transduction of nucleotide binding to the channel pore.

To investigate this further, we excised patches expressing W311\*,C166S-GFP+SUR1 and measure current inhibition and fluorescence quenching by TNP-ATP simultaneously (Figure 5.3A). We found that the apparent affinity for nucleotide binding was indistinguishable from that for W311\*-GFP+SUR1, and similar to our observations in unroofed membranes (Figure ??, EC<sub>50</sub> of 26 μM to 218 μM). Consistent with the literature, we did observe a large reduction in the apparent sensitivity of W311\*,C166S-GFP+SUR1 currents to inhibition by TNP-ATP (IC<sub>50</sub> of at least 155 μM. Intuitively,



a change in nucleotide-dependent channel gating which is not accompanied by a change in nucleotide binding must be due (at least in part) to a change in the transduction of nucleotide binding to channel gating.

Fitting our data to the MWC-type model described previously, we found that in

addition to the effects of the C166S mutation on the intrinsic open probability of  $K_{ATP}$ , there is a striking shift in  $D$  (Figure 5.4A). This shift to a value much closer to unity indicates that binding of TNP-ATP to W311\*,C166S-GFP+SUR1 favours the closed state far less than binding of TNP-ATP to W311\*-GFP+SUR1. Equivalently, binding of TNP-ATP to the mutant channel is less able to induce closure of the pore. Thus, even at millimolar concentrations of TNP-ATP when all of the Kir6.2 subunits are predicted to be bound, the  $K_{ATP}$  channels are still able to open.

This finding makes the prediction that nucleotide inhibition of  $K_{ATP}$  channels with the C166S mutation will exhibit a plateau of inhibition. Unfortunately, we were not able to test this directly with higher concentrations of TNP-ATP due to its purification as a TEA<sup>+</sup> salt. High mM concentrations of TEA<sup>+</sup> inhibit  $K_{ATP}$  channels, and we determined that for W311\*-GFP+SUR1 and W311\*,C166S-GFP+SUR1 concentrations of above 1 mM TEA<sup>+</sup> began to inhibit currents to an extent that would interfere with our measurements (Figure 5.4C, 5.4D). The precise ratio of TEA<sup>+</sup> to TNP-ATP in our solutions is unknown, but is assumed to be between 1:1 and 3:1. Any additional inhibition observed at TNP-ATP concentrations greater than 1 mM for W311\*,C166S-GFP+SUR1 will therefore be (at least in part) due to the presence of TEA<sup>+</sup>. However, we do see that even at concentrations of 10 mM ATP, W311\*,C166S-GFP+SUR1 is not fully inhibited (Figure ??, open circle). The literature is divided on the existence of a current plateau for mutations at C166, although these experiments have been performed under a variety of different conditions and with various different Kir6.2 backgrounds.

### 5.3.2 Mutations at E179 alter both inhibition and binding

Residue E179 of Kir6.2 is located in the C-terminal region of Kir6.2 between the inhibitory nucleotide binding site and the proposed PIP<sub>2</sub> binding site. In one early predicted structures of Kir6.2, it was theorised that E179 would form part of the nucleotide binding pocket directly, potentially coordinating the adenine ring of ATP directly through hydrogen bonding [38]. In another, it was hypothesised to form part of the PIP<sub>2</sub> binding pocket instead [39]. Electrophysiological experiments painted

a confusing picture of the residues role [38]. Mutation to an amino acid capable of forming hydrogen bonds (Q) resulted in no change in the IC<sub>50</sub> for nucleotide inhibition (although a separate study found that Q increased the IC<sub>50</sub> [40]), while only one of two amino acids incapable of forming hydrogen bonds tested (M and L) resulted in an increased IC<sub>50</sub>. In addition, mutation of the residue to asparagine (which is not capable of forming hydrogen bonds) not only dramatically increased the nucleotide IC<sub>50</sub>, but increased the intrinsic open probability of the channel [38].

The cryo-EM structures of K<sub>ATP</sub> in complex with ATP revealed that bound ATP adopted a radically different conformation to that proposed in early models, and the E179 side chain actually lies over 8 Å away from bound ATP [27–30]. Unfortunately, no structure has been resolved in the presence of PIP<sub>2</sub> to date. However, coarse-grained molecular dynamics simulations using the cryo-EM structures as a starting point indicate that E179 may form part of the PIP<sub>2</sub> binding pocket [41]. In addition, mutation to E179K results in reduced inhibition of the channel by the sequestering agent neomycin - potentially due to an increased affinity of the mutated residue for PIP<sub>2</sub> [41].

To attempt to resolve the precise role of E179 in nucleotide binding and inhibition, we first determined how ATP and TNP-ATP inhibiton of K<sub>ATP</sub> channels was affected by mutation of E179 to A or K. For E179A-GFP+SUR1 and E179K-GFP+SUR1, we observed an increase in IC<sub>50</sub> for both ATP and TNP-ATP inhibition. ATP inhibition did not seem to be influenced by the identity of the replacement amino acid (x and x respectively), while TNP-ATP inhibition was more reduced by mutation to a K rather than an A ( x and x respectively). Introducing the mutations into the ANAP-labelled construct did not affect the relative changes in inhibition by either nucleotide, with ATP inhibition occurring at similar IC<sub>50</sub>s for A and K (x and x respectively) and with K increasing the IC<sub>50</sub> for TNP-ATP more than A (x and x respectively). Measurements of TNP-ATP binding mirrored our observations for current inhibition by TNP-ATP, with mutation to both A and K resulting in an increased apparent binding EC<sub>50</sub>, with K having more of an effect than A (x and x respectively). Fitting the combined data to the MWC-type model, we found that both mutations resulted in a decreased

$K_A$  estimate, with no apparent change in  $L$ . In addition, mutation to a K led to a  $D$  value closer to unity than for E or A.

We believe there are two possible ways to interpret these findings. The first is to accept the shift in  $K_A$  at face value - a decrease in the apparent TNP-ATP binding affinity would suggest a role for residue E179 in forming the nucleotide binding pocket, and this function is abrogated by our mutations. Despite the distance of the residue from the bound ATP, there could be interactions between E179 and the sidechains of residues which do form the pocket (e.g. R54), such that mutation of E179 leads to alterations in the binding pocket which reduce nucleotide binding affinity and therefore our estimate of  $K_A$ . The additional effect on  $D$  caused by mutating the residue to K suggests a dysregulation of the transduction of nucleotide binding to the channel pore, making nucleotides less selective for the close state.

The second interpretation is possible due to the simplification of the role of PIP<sub>2</sub> in our MWC model as discussed previously. Briefly, if there is an additional allosteric interaction between nucleotide and PIP<sub>2</sub> binding to Kir6.2 which is separate to the channels open/closed state, then changes in  $K_A$  may reflect alterations in the affinity for PIP<sub>2</sub> binding in addition to or instead of alterations in the affinity for nucleotide binding. Thus, the decrease in  $K_A$  upon mutation of E179 may reflect an increase in PIP<sub>2</sub> affinity and demonstrate the presence of local allostery between nucleotide and lipid.

Distinguishing between these two interpretations is difficult given our current evidence, and essentially depends on the weight you place on the assumptions of each, but should be possible with one or two further experiments. Firstly, an increase in PIP<sub>2</sub> affinity should lead to an increase in channel open probability on excision (barring an effect on the relative preference of PIP<sub>2</sub> for the open state). Our inability to accurately determine the open probability of the macroscopic experiments described so far could be supplemented by single channel analysis of the mutants to test this directly. In addition, we could measure the affinity of PIP<sub>2</sub> directly in macroscopic patches. Finally, to definitively test the existence of local allostery between the nucleotide and PIP<sub>2</sub> binding sites, we could introduce

PIP<sub>2</sub> binding mutants into the C166S background. C166S channels exhibit almost no nucleotide-dependent gating; i.e. nucleotide binding is uncoupled from gating of the channel pore. Thus, any changes observed in nucleotide binding in the C166S background when PIP<sub>2</sub> affinity is changed must be due to a local allosteric interaction which does not involve the pore.

### 5.3.3 Mutations at K39 alter both inhibition and binding


Residue K39 of Kir6.2 is located in the N-terminal region of Kir6.2, and is positioned between the inhibitory nucleotide binding site and the proposed PIP<sub>2</sub> binding site. In previous studies, the mutation K39A has shown a small reduction in open probability [42], and a small reduction in sensitivity to nucleotide inhibition [42, 43]. These effects are somewhat contradictory, as mutations which reduce open probability tend also to increase sensitivity to nucleotide inhibition. In each of the cryo-EM structures of K<sub>ATP</sub>, the K39 side chain appears to coordinate the bound ATP molecule [27–30]. These structures are presumed to represent the closed state of the channel, and no PIP<sub>2</sub> bound structure of the channel has yet been solved. However, molecular dynamics simulations using the ATP-bound structure as a starting point and introducing PIP<sub>2</sub> suggest that the K39 residue is able to contact both ligands. This suggests a role for K39 in the binding sites of both ATP and PIP<sub>2</sub>, which may explain the contradictory findings on open probability and nucleotide inhibition changes when the residue is mutated.

We tested three mutations at K39 (K39A, K39E, K39R) to examine the effects of changing the side chain characteristics on nucleotide binding and inhibition. Mutation to E (opposite charge) or R (same charge) results in an increase in IC<sub>50</sub> for ATP inhibition for both WT and W311\* backgrounds (x for each). We did not see an increase in the IC<sub>50</sub> for ATP inhibition when K39 was mutated to A (neutral) in either background (x and x respectively). Inhibition by TNP-ATP displayed a different profile depending on the mutant residue. In both WT and W311\* backgrounds, inhibition by TNP-ATP exhibited higher IC<sub>50</sub> values for K39A and K39E than we observed for K39R, which was not really distinguishable from K39 (x for each). Our


docked conformation for TNP-ATP suggests that the TNP-moiety of the nucleotide may result in extra contacts with K39 compared to ATP, which may be the cause of the different sensitivity to inhibition between the two nucleotides when this residue is mutated. Measurements of TNP-ATP binding showed increases in the EC<sub>50</sub> estimates for each of the three mutations (x for each).

Fits of the combined data to the MWC model gave parameter estimates for  $K_A$  that decreased from K>R>E>A. In addition, mutation to an E or an A resulted in  $D$  values closer to unity. Interpretation of these parameters for the R and A mutations is frustrated by the differences in inhibition between TNP-ATP and ATP; we cannot be sure that these differences in binding and inhibition are due to the identity of the nucleotide rather than the identity of the residue. However, the K39E mutation displayed similar inhibition for both TNP-ATP and ATP. The increase in our estimate for  $D$  when K39 is mutated to an A or an E, but not for R, may indicate a positive charge at the sidechain of this residue being important for transduction of nucleotide binding to the channel pore.

## 5.4 Discussion



**FIGURE 5.3:** **A** Current inhibition (left) and fluorescence quenching (right) from an excised patch expressing W311\*,C166S-GFP+SUR1. The concentration of TNP-ATP perfused is shown by colour. The location of the peak ANAP fluorescence is marked as a grey box. **B** Fluorescence quenching of W311\*,C166S-GFP+SUR1 by TNP-ATP in excised patches. Each point represents an individual experiment. The smooth filled curves are the 95 % intervals of the posterior probability distribution of fits to equation 2.2 as described in the methods. **C** Current inhibition of W311\*,C166S-GFP+SUR1 by TNP-ATP in excised patches. Each point represents an individual experiment. The smooth filled curves are the 95 % intervals of the posterior probability distribution of fits to equation 2.2 as described in the methods. **D** Posterior probability distributions for the estimated population  $EC_{50}$  (blue) and  $IC_{50}$  (orange) values are shown shaded according to their intervals. **E** Data from each experiment is shown separately; each column represents one excised patch.. The smooth filled curves are the 95 % intervals of the posterior predictions for each experiment.





# 6

## Regulation of Kir6.2 by SUR1

### Contents

---

6.1	Introduction	71
6.2	Intrinsic effects of SUR1	72
6.2.1	SUR1 alters nucleotide inhibition, but not binding	72
6.2.2	Presence of SUR1-TMD0 alone does not alter apparent nucleotide binding	74
6.3	SUR1 and nucleotide regulation	74
6.3.1	Mutations at SUR-K205 alter nucleotide binding and inhibition	74
6.4	Discussion	76

---

### 6.1 Introduction

The SUR1 subunit exerts a number of different regulatory effects on the K<sub>ATP</sub> channel. Firstly, it dramatically enhances trafficking of Kir6.2 to the cell membrane by masking the endoplasmic retention motif in Kir6.2 (RKR). Without coexpression with SUR1, Kir6.2 is confined to the endoplasmic reticulum. Truncating the C-terminal by deleting the last 26 (Kir6.2-ΔC26) or 36 (Kir6.2-ΔC36) amino acids [44], mutation of the RKR motif to AAA [45], or addition of a C-terminal GFP tag [46] are sufficient to allow expression of Kir6.2 at the membrane alone without the presence of SUR1. Comparing the function of these modified Kir6.2 subunits alone to the function of

octameric K<sub>ATP</sub> channels makes it possible to discern the multifaceted roles of SUR1. Crucially, these C-terminal modifications do not appear to alter K<sub>ATP</sub> function when they are coexpressed with SUR1 [33, 44, 46] and the cryo-EM structure solved for C-terminally GFP labelled Kir6.2 [29] was highly similar to those solved without the GFP label [47, 48].

Coexpression of SUR1 has two effects on K<sub>ATP</sub> channel function. Firstly, SUR1 increases the  $P_O$  of the channel [44, 46, 49]. Expressing the TMD0 region of SUR1 (residues 1 - 195) alone is sufficient to recapitulate the increase in  $P_O$  observed when full-length SUR1 is coexpressed[49, 50]. When TMD0 is coexpressed with Kir6.2, there is additionally a decrease in the sensitivity of Kir6.2 to nucleotide inhibition - allosterically, an increase in  $P_O$  would result in a decrease in apparent ATP affinity due to the reduction in stability of the closed state. However, when full length SUR1 is coexpressed with Kir6.2, there is a marked increase in sensitivity to ATP inhibition [33, 44, 46, 49]. This increase in sensitivity is not due to the L0 linker, the other domain of SUR1 postulated to make contacts with Kir6.2. Expression of TMD0-L0 (residues 1 - 232) with Kir6.2 increases the  $P_O$  to nearly saturating, and reduces ATP inhibition even further [50]. Increasing the fraction of L0 (up to residue number 256 or 288) attenuates this increase in  $P_O$ , but there is not the dramatic increase in ATP sensitivity observed from expression of full-length SUR1, implicating a role for the core region of SUR1 in regulating nucleotide binding and inhibition [51].

## 6.2 Intrinsic effects of SUR1


### 6.2.1 SUR1 alters nucleotide inhibition, but not binding

Expressing WT-GFP alone without SUR1 results in smaller, noisier currents than when coexpressed with SUR1. Currents are less sensitive to ATP and TNP-ATP by an order of magnitude (x and x). Our surface expression assay suggested that while WT-GFP was able to reach the membrane in the absence of SUR1, W311\*-GFP was not, and when we excised patches from cells expressing W311\*-GFP alone, we were not able to resolve any currents. We were still able to resolved fluorescence in unroofed

membranes expressing W311\*-GFP alone, and so we measured binding of TNP-ATP to W311\*-GFP alone in unroofed membranes. We observed very minimal differences in the EC<sub>50</sub> for binding. However, given that we did not observe currents under these experimental conditions, we cannot determine the functional state of these channels and so this finding may not be representative for K<sub>ATP</sub> channels physiologically.

Given that we were able to observe currents in the absence of SUR1, we confirmed that when SUR1 was cotransfected with our constructs we were measuring currents and fluorescence from correctly assembled K<sub>ATP</sub> channels. Firstly, we used tolbutamide to inhibit excised patches from cells expressing either WT-GFP alone, WT-GFP+SUR1 or W311\*-GFP+SUR1. Tolbutamide inhibition occurs at two sites on the K<sub>ATP</sub> channel; a high affinity site on SUR1 and a low affinity site on Kir6.2 [52, 53]. Inhibition occurring at these two sites can be well separated, with the high affinity site saturating at 100 µM tolbutamide at 50 % fractional inhibition. Tolbutamide inhibition of Kir6.2 expressed alone does not display inhibition until concentrations of over 100 µM. When we expressed WT-GFP alone, we saw no inhibition of currents by 100 µM, whereas when we expressed WT-GFP+SUR1 or W311\*-GFP+SUR1, we observed roughly a 50 % fractional inhibition of current as expected for proper association of Kir6.2 and SUR1.

In addition, we labelled the C-terminus of SUR1 with the fluorophore mOrange (SUR1-mO), and measured FRET between the GFP on WT-GFP or W311\*-GFP and the mOrange on SUR1 in unroofed membranes. The cryo-EM structures suggest a distance between the C-termini of Kir6.2 and SUR1 of roughly 60 Å, while the GFP-mOrange FRET pair has a theoretical R<sub>0</sub> of 54 Å. We would therefore expect to see FRET if our Kir6.2 and SUR1 constructs are coassembling. To measure FRET, we used an approach described in [54] whereby FRET is measured as an increase in the emission of the acceptor fluorophore (mOrange) on excitation of the donor fluorophore (GFP) (Figure ??). We observed FRET between WT-GFP and SUR1-mO, consistent with the two subunits being in close proximity. Less FRET was observed when W311\*-GFP was coexpressed with SUR1-mO (although still much



higher than background). This is probably due to the reduced expression of W311\*-GFP compared to WT-GFP, i.e. there is less donor fluorescence to transfer to mOrange. Correcting for the magnitude of the GFP peak results in observed ratios for WT-GFP and W311\*-GFP that are very similar.

### 6.2.2 Presence of SUR1-TMD0 alone does not alter apparent nucleotide binding

## 6.3 SUR1 and nucleotide regulation

### 6.3.1 Mutations at SUR-K205 alter nucleotide binding and inhibition

Residue K205 of SUR1 is located in the L0 region which links TMD0 and TMD1. While expression of Kir6.2 and TMD0-L0 have shown that the region is important in




FIGURE 6.2

modulating the  $P_O$  of K<sub>ATP</sub> channels [49, 55, 56], it does not confer the high sensitivity to ATP inhibition seen in Kir6.2+SUR1 channels. It has therefore been suggested that the elements of SUR1 which contribute to the higher sensitivity of K<sub>ATP</sub> channels to ATP inhibition lie outside of this region [55, 57]. However, the cryo-EM structures of K<sub>ATP</sub> suggest a close proximity between L0 and the ATP binding pocket [29, 47, 48] and mutations in this region reduce the sensitivity of K<sub>ATP</sub> to nucleotide inhibition [57–59]. Mutation of K205 to A [58] or E [58] have resulted in marked reduction of K<sub>ATP</sub> channel sensitivity to nucleotide inhibition. Why would mutation of this residue in L0 affect nucleotide inhibition given that expression of the L0 region does not in itself affect nucleotide inhibition?

We excised patches expressing W311\*-GFP+SUR1-K205A or W311\*-GFP+SUR1-K205E and measured current inhibition and fluorescence quenching by TNP-ATP simultaneously. We found that both substitutions resulted in an increased IC<sub>50</sub> for TNP-ATP inhibition and an increased EC<sub>50</sub> for TNP-ATP binding, with K205E exhibiting a more pronounced effect than K205A. Fitting the data to our MWC model gave parameter estimates for  $K_A$  which were reduced when compared to wild-type SUR1; with the neutral mutation K205A not affecting  $K_A$  quite as much as the charge





FIGURE 6.3

reversal mutation K205E. In addition, both mutations led to similar increases in *D*. Thus, the reduced sensitivity to nucleotide inhibition is due to a combination of reduced apparent binding affinity in addition to reduced stabilisation of the closed state of the channel by nucleotides.

## 6.4 Discussion

Expression of W311\*-GFP in the absence of SUR1, or in the presence of SUR1 truncated to the TMD0 or TMD0-L0 regions alone does not appear to affect nucleotide binding directly. When current inhibition is measured, we see TMD0-232 decreases

$K_{ATP}$  sensitivity to nucleotide inhibition as seen in previous studies. So why do mutations in L0 reduce sensitivity to nucleotide inhibition and cause neonatal diabetes? Measuring binding directly allows us to address this problem. We found that K205, a residue in L0, does in fact contribute to the nucleotide binding site. This alone is not enough to explain the change in nucleotide inhibition. Our novel finding is that mutating this residue alters the ability of TNP-ATP to close the channel. This is consistent with the hypothesis that L0 plays a key role in tuning the modulatory function of nucleotides on Kir6.2. The wild-type residue K205 is at least partly responsible for the strong coupling of nucleotide binding to channel inhibition. But this does not explain why TMD0-L0 expression is not enough to restore full-length SUR1 like nucleotide inhibition. Future experiments - residue E128 potentially plays a similar role for PIP2.

**6.4. Discussion**

# 7

## Discussion



# **Appendices**



# References

1. Tanabe, K. *et al.* Direct Photoaffinity Labeling of the Kir6.2 Subunit of the ATP-sensitive K<sup>+</sup> Channel by 8-Azido-ATP\*. en. *Journal of Biological Chemistry* **274**, 3931–3933.  
<https://www.sciencedirect.com/science/article/pii/S0021925819878626> (2021) (Feb. 1999).
2. Vanoye, C. G. *et al.* The carboxyl termini of K(ATP) channels bind nucleotides. *J Biol Chem* **277**. Type: Journal Article, 23260–70.  
<https://www.ncbi.nlm.nih.gov/pubmed/11956191> (2002).
3. Thomas, P., Ye, Y. & Lightner, E. Mutation of the Pancreatic Islet Inward Rectifier Kir6.2 Also Leads to Familial Persistent Hyperinsulinemic Hypoglycemia of Infancy. *Human Molecular Genetics* **5**, 1809–1812.  
<https://doi.org/10.1093/hmg/5.11.1809> (2021) (Nov. 1996).
4. Tornovsky, S. *et al.* Hyperinsulinism of Infancy: Novel ABCC8 and KCNJ11 Mutations and Evidence for Additional Locus Heterogeneity. *The Journal of Clinical Endocrinology & Metabolism* **89**, 6224–6234.  
<https://doi.org/10.1210/jc.2004-1233> (2021) (Dec. 2004).
5. Martin, G. M., Chen, P.-C., Devaraneni, P. & Shyng, S.-L. Pharmacological rescue of trafficking-impaired ATP-sensitive potassium channels. English. *Frontiers in Physiology* **4**. Publisher: Frontiers.  
<https://www.frontiersin.org/articles/10.3389/fphys.2013.00386/full> (2021) (2013).
6. Lin, C.-W. *et al.* Kir6.2 Mutations Associated With Neonatal Diabetes Reduce Expression of ATP-Sensitive K<sup>+</sup> channels: Implications in Disease Mechanism and Sulfonylurea Therapy. en. *Diabetes* **55**. Publisher: American Diabetes Association Section: Genetics, 1738–1746.  
<https://diabetes.diabetesjournals.org/content/55/6/1738> (2021) (June 2006).
7. Cartier, E. A., Conti, L. R., Vandenberg, C. A. & Shyng, S.-L. Defective trafficking and function of KATP channels caused by a sulfonylurea receptor 1 mutation associated with persistent hyperinsulinemic hypoglycemia of infancy. en. *Proceedings of the National Academy of Sciences* **98**. Publisher: National Academy of Sciences Section: Biological Sciences, 2882–2887. <https://www.pnas.org/content/98/5/2882> (2021) (Feb. 2001).
8. Marthinet, E. *et al.* Severe Congenital Hyperinsulinism Caused by a Mutation in the Kir6.2 Subunit of the Adenosine Triphosphate-Sensitive Potassium Channel Impairing Trafficking and Function. *The Journal of Clinical Endocrinology & Metabolism* **90**, 5401–5406. <https://doi.org/10.1210/jc.2005-0202> (2021) (Sept. 2005).

9. Shyng, S.-L. & Nichols, C. G. Membrane Phospholipid Control of Nucleotide Sensitivity of KATP Channels. en. *Science* **282**. Publisher: American Association for the Advancement of Science Section: Report, 1138–1141.  
<https://science.sciencemag.org/content/282/5391/1138> (2021) (Nov. 1998).
10. Nichols, C. G. et al. Adenosine Diphosphate as an Intracellular Regulator of Insulin Secretion. en. *Science* **272**. Publisher: American Association for the Advancement of Science Section: Reports, 1785–1787.  
<https://science.sciencemag.org/content/272/5269/1785> (2021) (June 1996).
11. Gribble, F. M., Tucker, S. J. & Ashcroft, F. M. The essential role of the Walker A motifs of SUR1 in K-ATP channel activation by Mg-ADP and diazoxide. *The EMBO Journal* **16**. Publisher: John Wiley & Sons, Ltd, 1145–1152.  
<https://www.embopress.org/doi/full/10.1093/emboj/16.6.1145> (2021) (Mar. 1997).
12. Shyng, S.-L., Ferrigni, T. & Nichols, C. Regulation of KATP Channel Activity by Diazoxide and MgADP : Distinct Functions of the Two Nucleotide Binding Folds of the Sulfonylurea Receptor. *Journal of General Physiology* **110**, 643–654.  
<https://doi.org/10.1085/jgp.110.6.643> (2021) (Dec. 1997).
13. Ashcroft, F. M. & Rorsman, P. K ATP channels and islet hormone secretion: new insights and controversies. en. *Nature Reviews Endocrinology* **9**. Number: 11 Publisher: Nature Publishing Group, 660–669.  
<https://www.nature.com/articles/nrendo.2013.166> (2021) (Nov. 2013).
14. Hattersley, A. T. & Ashcroft, F. M. Activating Mutations in Kir6.2 and Neonatal Diabetes: New Clinical Syndromes, New Scientific Insights, and New Therapy. en. *Diabetes* **54**. Publisher: American Diabetes Association Section: Perspectives in Diabetes, 2503–2513.  
<https://diabetes.diabetesjournals.org/content/54/9/2503> (2021) (Sept. 2005).
15. Nichols, C. G. K ATP channels as molecular sensors of cellular metabolism. en. *Nature* **440**. Number: 7083 Publisher: Nature Publishing Group, 470–476.  
<https://www.nature.com/articles/nature04711> (2021) (Mar. 2006).
16. Aguilar-Bryan, L. & Bryan, J. Neonatal Diabetes Mellitus. *Endocrine Reviews* **29**, 265–291. <https://doi.org/10.1210/er.2007-0029> (2021) (May 2008).
17. Flanagan, S. E. et al. Update of mutations in the genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. en. *Human Mutation* **30**. \_eprint: <https://onlinelibrary.wiley.com/doi/pdf/10.1002/humu.20838>, 170–180.  
<https://onlinelibrary.wiley.com/doi/abs/10.1002/humu.20838> (2021) (2009).
18. Ashcroft, F. M. & Rorsman, P. Diabetes Mellitus and the Beta Cell: The Last Ten Years. English. *Cell* **148**. Publisher: Elsevier, 1160–1171.  
[https://www.cell.com/cell/abstract/S0092-8674\(12\)00208-5](https://www.cell.com/cell/abstract/S0092-8674(12)00208-5) (2021) (Mar. 2012).
19. Ashcroft, F. M. & Rorsman, P. K(ATP) channels and islet hormone secretion: new insights and controversies. *Nat Rev Endocrinol* **9**. Type: Journal Article, 660–9.  
<https://www.ncbi.nlm.nih.gov/pubmed/24042324> (2013).

20. Ashcroft, F. M., Puljung, M. C. & Vedovato, N. Neonatal Diabetes and the KATP Channel: From Mutation to Therapy. en. *Trends in Endocrinology & Metabolism* **28**, 377–387.  
<http://www.sciencedirect.com/science/article/pii/S104327601730019X> (2021) (May 2017).
21. Rorsman, P. & Ashcroft, F. M. Pancreatic beta-Cell Electrical Activity and Insulin Secretion: Of Mice and Men. *Physiological Reviews* **98**. Publisher: American Physiological Society, 117–214.  
<https://journals.physiology.org/doi/full/10.1152/physrev.00008.2017> (2021) (Dec. 2017).
22. Pipatpolkai, T., Usher, S., Stansfeld, P. J. & Ashcroft, F. M. New insights into K ATP channel gene mutations and neonatal diabetes mellitus. en. *Nature Reviews Endocrinology* **16**. Number: 7 Publisher: Nature Publishing Group, 378–393.  
<https://www.nature.com/articles/s41574-020-0351-y> (2021) (July 2020).
23. Drain, P., Li, L. & Wang, J. KATP channel inhibition by ATP requires distinct functional domains of the cytoplasmic C terminus of the pore-forming subunit. en. *Proceedings of the National Academy of Sciences* **95**. Publisher: National Academy of Sciences Section: Biological Sciences, 13953–13958.  
<https://www.pnas.org/content/95/23/13953> (2021) (Nov. 1998).
24. Li, L., Geng, X. & Drain, P. Open State Destabilization by Atp Occupancy Is Mechanism Speeding Burst Exit Underlying KATP Channel Inhibition by Atp. *Journal of General Physiology* **119**, 105–116. <https://doi.org/10.1085/jgp.119.1.105> (2021) (Jan. 2002).
25. Li, L. et al. Ligand-dependent Linkage of the ATP Site to Inhibition Gate Closure in the KATP Channel. *Journal of General Physiology* **126**, 285–299.  
<https://doi.org/10.1085/jgp.200509289> (2021) (Aug. 2005).
26. Masia, R. et al. An ATP-Binding Mutation (G334D) in KCNJ11 Is Associated With a Sulfonylurea-Insensitive Form of Developmental Delay, Epilepsy, and Neonatal Diabetes. en. *Diabetes* **56**. Publisher: American Diabetes Association Section: Islet Studies, 328–336. <https://diabetes.diabetesjournals.org/content/56/2/328> (2021) (Feb. 2007).
27. Lee, K. P. K., Chen, J. & MacKinnon, R. Molecular structure of human KATP in complex with ATP and ADP. *Elife* **6**. Type: Journal Article.  
<https://www.ncbi.nlm.nih.gov/pubmed/29286281> (2017).
28. Martin, G. M., Kandasamy, B., DiMaio, F., Yoshioka, C. & Shyng, S. L. Anti-diabetic drug binding site in a mammalian KATP channel revealed by Cryo-EM. *Elife* **6**. Type: Journal Article. <https://www.ncbi.nlm.nih.gov/pubmed/29035201> (2017).
29. Li, N. et al. Structure of a Pancreatic ATP-Sensitive Potassium Channel. en. *Cell* **168**, 101–110.e10.  
<http://www.sciencedirect.com/science/article/pii/S0092867416317445> (2021) (Jan. 2017).
30. Puljung, M. C. Cryo-electron microscopy structures and progress toward a dynamic understanding of KATP channels. *J Gen Physiol* **150**. Type: Journal Article, 653–669.  
<https://www.ncbi.nlm.nih.gov/pubmed/29685928> (2018).

31. Gloyn, A. L. *et al.* KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features. *Eur J Hum Genet* **14**. Type: Journal Article, 824–30.  
<https://www.ncbi.nlm.nih.gov/pubmed/16670688> (2006).
32. Trapp, S., Proks, P., Tucker, S. J. & Ashcroft, F. M. Molecular analysis of ATP-sensitive K channel gating and implications for channel inhibition by ATP. *J Gen Physiol* **112**. Type: Journal Article, 333–49. <https://www.ncbi.nlm.nih.gov/pubmed/9725893> (1998).
33. Ribalet, B., John, S. A., Xie, L. H. & Weiss, J. N. ATP-sensitive K<sup>+</sup> channels: regulation of bursting by the sulphonylurea receptor, PIP2 and regions of Kir6.2. *J Physiol* **571**. Type: Journal Article, 303–17. <https://www.ncbi.nlm.nih.gov/pubmed/16373383> (2006).
34. Yang, H.-Q. *et al.* Palmitoylation of the KATP channel Kir6.2 subunit promotes channel opening by regulating PIP2 sensitivity. en. *Proceedings of the National Academy of Sciences* **117**. Publisher: National Academy of Sciences Section: Biological Sciences, 10593–10602. <https://www.pnas.org/content/117/19/10593> (2021) (May 2020).
35. Loussouarn, G., Makhina, E. N., Rose, T. & Nichols, C. G. Structure and Dynamics of the Pore of Inwardly Rectifying KATP Channels\*. en. *Journal of Biological Chemistry* **275**, 1137–1144.  
<https://www.sciencedirect.com/science/article/pii/S0021925818312286> (2021) (Jan. 2000).
36. Enkvetchakul, D., Loussouarn, G., Makhina, E., Shyng, S. L. & Nichols, C. G. The kinetic and physical basis of K(ATP) channel gating: toward a unified molecular understanding. *Biophys J* **78**. Type: Journal Article, 2334–48.  
<https://www.ncbi.nlm.nih.gov/pubmed/10777731> (2000).
37. Li, J. B. W. *et al.* Decomposition of Side Helix Contributions to ATP-dependent Inhibition of Kir6.2 Channels\*. en. *Journal of Biological Chemistry* **288**, 23038–23049. <https://www.sciencedirect.com/science/article/pii/S002192582045330X> (2021) (Aug. 2013).
38. Antcliff, J. F., Haider, S., Proks, P., Sansom, M. S. & Ashcroft, F. M. Functional analysis of a structural model of the ATP-binding site of the KATP channel Kir6.2 subunit. *The EMBO Journal* **24**. Publisher: John Wiley & Sons, Ltd, 229–239.  
<https://www.embopress.org/doi/full/10.1038/sj.emboj.7600487> (2021) (Jan. 2005).
39. Haider, S., Tarasov, A. I., Craig, T. J., Sansom, M. S. & Ashcroft, F. M. Identification of the PIP2-binding site on Kir6.2 by molecular modelling and functional analysis. *The EMBO Journal* **26**. Publisher: John Wiley & Sons, Ltd, 3749–3759.  
<https://www.embopress.org/doi/full/10.1038/sj.emboj.7601809> (2021) (Aug. 2007).
40. Proks, P., Gribble, F. M., Adhikari, R., Tucker, S. J. & Ashcroft, F. M. Involvement of the N-terminus of Kir6.2 in the inhibition of the KATP channel by ATP. en. *The Journal of Physiology* **514**. \_eprint:  
<https://physoc.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1469-7793.1999.019af.x>, 19–25. <https://physoc.onlinelibrary.wiley.com/doi/abs/10.1111/j.1469-7793.1999.019af.x> (2021) (1999).

41. Pipatpolkai, T., Corey, R. A., Proks, P., Ashcroft, F. M. & Stansfeld, P. J. Evaluating inositol phospholipid interactions with inward rectifier potassium channels and characterising their role in disease. en. *Communications Chemistry* **3**. Number: 1 Publisher: Nature Publishing Group, 1–10. <https://www.nature.com/articles/s42004-020-00391-0> (2021) (Oct. 2020).
42. Cukras, C., Jeliazkova, I. & Nichols, C. The Role of NH<sub>2</sub>-terminal Positive Charges in the Activity of Inward Rectifier KATP Channels. *Journal of General Physiology* **120**, 437–446. <https://doi.org/10.1085/jgp.20028621> (2021) (Aug. 2002).
43. Tucker, S. J. et al. Molecular determinants of KATP channel inhibition by ATP. *The EMBO Journal* **17**. Publisher: John Wiley & Sons, Ltd, 3290–3296. <https://www.embopress.org/doi/full/10.1093/emboj/17.12.3290> (2021) (June 1998).
44. Tucker, S. J., Gribble, F. M., Zhao, C., Trapp, S. & Ashcroft, F. M. Truncation of Kir6.2 produces ATP-sensitive K<sup>+</sup> channels in the absence of the sulphonylurea receptor. en. *Nature* **387**. Number: 6629 Publisher: Nature Publishing Group, 179–183. <https://www.nature.com/articles/387179a0> (2021) (May 1997).
45. Zerangue, N., Schwappach, B., Jan, Y. N. & Jan, L. Y. A New ER Trafficking Signal Regulates the Subunit Stoichiometry of Plasma Membrane KATP Channels. English. *Neuron* **22**. Publisher: Elsevier, 537–548. [https://www.cell.com/neuron/abstract/S0896-6273\(00\)80708-4](https://www.cell.com/neuron/abstract/S0896-6273(00)80708-4) (2021) (Mar. 1999).
46. John, S. A., Monck, J. R., Weiss, J. N. & Ribalet, B. The sulphonylurea receptor SUR1 regulates ATP-sensitive mouse Kir6.2 K<sup>+</sup> channels linked to the green fluorescent protein in human embryonic kidney cells (HEK 293). *J Physiol* **510** (Pt 2). Type: Journal Article, 333–45. <https://www.ncbi.nlm.nih.gov/pubmed/9705987> (1998).
47. Martin, G. M., Kandasamy, B., DiMaio, F., Yoshioka, C. & Shyng, S.-L. Anti-diabetic drug binding site in a mammalian KATP channel revealed by Cryo-EM. *eLife* **6** (ed Swartz, K. J.) Publisher: eLife Sciences Publications, Ltd, e31054. <https://doi.org/10.7554/eLife.31054> (2021) (Oct. 2017).
48. Lee, K. P. K., Chen, J. & MacKinnon, R. Molecular structure of human KATP in complex with ATP and ADP. *eLife* **6** (ed Swartz, K. J.) Publisher: eLife Sciences Publications, Ltd, e32481. <https://doi.org/10.7554/eLife.32481> (2021) (Dec. 2017).
49. Chan, K. W., Zhang, H. & Logothetis, D. E. N-terminal transmembrane domain of the SUR controls trafficking and gating of Kir6 channel subunits. *The EMBO Journal* **22**. Publisher: John Wiley & Sons, Ltd, 3833–3843. <https://www.embopress.org/doi/full/10.1093/emboj/cdg376> (2021) (Aug. 2003).
50. Babenko, A. P. & Bryan, J. SUR Domains That Associate with and Gate KATP Pores Define a Novel Gatekeeper\*. en. *Journal of Biological Chemistry* **278**, 41577–41580. <https://www.sciencedirect.com/science/article/pii/S0021925820826805> (2021) (Oct. 2003).
51. Puljung, M. C. Cryo-electron microscopy structures and progress toward a dynamic understanding of KATP channels. *Journal of General Physiology* **150**, 653–669. <https://doi.org/10.1085/jgp.201711978> (2021) (Apr. 2018).

52. Gribble, F. M., Tucker, S. J., Seino, S. & Ashcroft, F. M. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. en. *Diabetes* **47**. Publisher: American Diabetes Association, 1412–1418.  
<https://diabetes.diabetesjournals.org/content/47/9/1412> (2021) (Sept. 1998).
53. Ashfield, R., Gribble, F. M., Ashcroft, S. J. & Ashcroft, F. M. Identification of the high-affinity tolbutamide site on the SUR1 subunit of the K(ATP) channel. en. *Diabetes* **48**. Publisher: American Diabetes Association, 1341–1347.  
<https://diabetes.diabetesjournals.org/content/48/6/1341> (2021) (June 1999).
54. Zheng, J., Trudeau, M. C. & Zagotta, W. N. Rod Cyclic Nucleotide-Gated Channels Have a Stoichiometry of Three CNGA1 Subunits and One CNGB1 Subunit. en. *Neuron* **36**, 891–896.  
<https://www.sciencedirect.com/science/article/pii/S0896627302010991> (2021) (Dec. 2002).
55. Babenko, A. P. & Bryan, J. Sur domains that associate with and gate KATP pores define a novel gatekeeper. *J Biol Chem* **278**. Type: Journal Article, 41577–80.  
<https://www.ncbi.nlm.nih.gov/pubmed/12941953> (2003).
56. Pratt, E. B., Tewson, P., Bruederle, C. E., Skach, W. R. & Shyng, S.-L. N-terminal transmembrane domain of SUR1 controls gating of Kir6.2 by modulating channel sensitivity to PIP2. *Journal of General Physiology* **137**, 299–314.  
<https://doi.org/10.1085/jgp.201010557> (2021) (Feb. 2011).
57. Pratt, E. B., Zhou, Q., Gay, J. W. & Shyng, S.-L. Engineered interaction between SUR1 and Kir6.2 that enhances ATP sensitivity in KATP channels. *Journal of General Physiology* **140**, 175–187. <https://doi.org/10.1085/jgp.201210803> (2021) (July 2012).
58. Ding, D., Wang, M., Wu, J. X., Kang, Y. & Chen, L. The Structural Basis for the Binding of Repaglinide to the Pancreatic KATP Channel. *Cell Rep* **27**. Type: Journal Article, 1848–1857 e4. <https://www.ncbi.nlm.nih.gov/pubmed/31067468> (2019).
59. Masia, R. et al. A Mutation in the TMD0-L0 Region of Sulfonylurea Receptor-1 (L225P) Causes Permanent Neonatal Diabetes Mellitus (PNDM). en. *Diabetes* **56**. Publisher: American Diabetes Association Section: Brief Reports, 1357–1362.  
<https://diabetes.diabetesjournals.org/content/56/5/1357> (2021) (May 2007).